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Differential effects of cannabis use on event-related potential (ERP)-indexes of cortical 
inhibition in cannabis users and non-users.  
 
August 27th 2021  
 
By Ashley Morgan  Francis 
 
Cannabis has psychoactive properties and is thought to be associated 
with potential structural and functional changes with early and heavy use. Previous 
research suggests cannabis users (CU) vs. non-users (NU) have deficits on EEG-
derived event-related potentials elicited by  paired click and visual Go/NoGo paradigms. 
We used these paradigms to examine inhibitory functioning in CUs (n = 14; 9 
male) vs. NUs (n = 16, 4 male). Effect sizes suggest CUs had impaired N100 measures of 
sensory gating compared to NUs. Additionally, a trend level interaction and latency 
findings for the P200 suggested CUs had smaller amplitudes and quicker latencies to 
S1 compared to NUs. Go/NoGo findings revealed enhanced P100 amplitudes in CUs (vs. 
NUs). No other between-group differences or sex differences were observed. This study 
provides further support for cannabis-induced deficits on early-attentional processing as 
indexed by the N100 and novel findings regarding enhanced P100 amplitudes to the 
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Chapter 1: Introduction 
1.1 Cannabis and the Endogenous Cannabinoid System 
Cannabis is a term used to refer to any consumable product obtained from a 
species of the Cannabaceae family. This plant’s primary psychoactive ingredient, delta-
9-tetrahydrocannabinol (THC), acts on the brain and central nervous system (CNS) 
through its interaction with the endocannabinoid system (Böcker et al., 2010). The 
endocannabinoid system is comprised of CB1 and CB2 receptors (CB1R and CB2R 
respectively), as well as the endogenous cannabinoids anandamide and 2-arachidonoyl 
glycerol (2-AG; Devane et al., 1992). CB1 receptors are primarily found in the brain and 
central nervous system (Mechoulam & Parker, 2013).  It was long believed that CB2 
receptors were more commonly found in the peripheral nervous system (PNS; Munro, 
Thomas, & Abu-Shaar, 1993), with the exception of some being located throughout the 
brain in areas of the vagus nerve and brain stem (Sickle et al., 2005). A recent review of 
the current literature, however, suggests otherwise, providing evidence of CB2 receptors 
in the human brain (Jordan et al., 2018), specifically in areas of the hippocampus 
(Stempel et al., 2016) and cortical pyramidal neurons (Garcia-Gutierrez et al., 2018). 
CB1 receptors, which are the primary site of action for the psychoactive effects of 
cannabis, are particularly dense in brain areas such as the prefrontal and cingulate 
cortices (Eggan & Lewis, 2007) as well as the hippocampus (Herkenham, 1991; Katona 
et al., 2006), basal ganglia (Herkenham, 1991), and white matter tracts (Crocker & Tibbo, 
2015; Renard et al., 2014). These areas are especially important when considering the 
effects of cannabis on neural and cognitive functioning such as inhibitory control and 
working memory. The location of these CB1 receptors suggests that they play a role in 
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cognition and motivation. It has also been observed that the distribution and quantity of 
CB1 receptors varies across the lifespan, with high levels of CB1 receptors and 
endocannabinoids being present in children and adolescents only to decrease as 
individuals mature into adulthood (Crocker & Tiboo, 2015; Mechoulam & Parker, 2013). 
In addition to changes in receptor density relative to age, sex differences have also been 
observed (Van Laere et al., 2008), although findings are mixed. Specifically, some 
studies show that females have a significant increase in CB1 receptors as they age (Van 
Laere et al., 2008). Other more recent studies, show males have a higher volume of 
receptors across all brain regions (Laurikainen et al., 2019). Laurikainen et al. (2019) 
found that females using oral contraceptives tended to have decreased receptor volumes 
when compared to naturally cycling females, thus suggesting hormonal birth control may 
be an important factor to consider when conducting cannabis, brain-based research.  
Structural changes have also been reported in heavy cannabis users, with the most 
common changes being reported in relation to hippocampal volume and grey matter 
density, such that with an increase in cannabis use there was a decrease in hippocampal 
volume and grey matter density (Ashtari et al.,2011; Battistella et al.,2014; Demirakca et 
al.,2011; Yücel et al.,2008, 2016). In addition, executive functioning, working memory, 
and attention were highlighted as areas that appear to be most heavily impacted by 
cannabis use (see Nader and Sanchez 2018 for full review). With the recent legalization 
of this potentially neurotoxic substance in our country, it is critical that we better 
understand the implications this drug can have on the human brain. 
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1.2 Cannabis Use Across North America  
The legalization of cannabis is becoming more prominent worldwide, allowing 
the medical properties of the drug to become more well known. Legalization of the drug 
cannabis, however, can lead to a decrease in the perceived risk of using cannabis (Cuttler 
et al., 2016’ Johnson et al.,2011). This is concerning given that relatively little is known 
about how the drug affects the developing human brain. Johnston et al. (2011) found that 
as the perceived risk of using cannabis decreased, the overall use of cannabis increased – 
particularly in adolescents between the ages of 13-18. Cannabis use risk is also related to 
outcome expectancies (beliefs about the effects of the drug). For example, one study 
asked students to self-generate expectancies of using cannabis; when students rated their 
expectancies as positive, they were more likely to be cannabis users by grade 7 compared 
to if they rated the expectancies as negative (Fulton et al., 2012).  
In the United States of America (USA), cannabis use has significantly increased 
from 2018 – 2019 (U.S Department of Health and Human Services, 2019). Despite the 
increased usage, the age of substance use onset has remained relatively consistent with 
most individuals commencing in early-to-mid adolescence worldwide. Canada 
specifically reports an average age of initiation between 14.2 years (the 2016/17 
Canadian Tobacco Alcohol and Drugs Survey [CTADS]) and 19.2 years (the 2019 
Canadian Cannabis Survey [CCS]) (Červený et al., 2017; Chen et al.,2017; United 
Nations Office on Drugs and Crime 2018). However, the latter is potentially biased by 
the age of respondents and greater reliance on retrospective memory as it surveyed 
individuals 16 years of age and older; therefore, these two findings cannot be directly 
compared. Furthermore, substance use rates have been shown to peak at certain ages 
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(e.g., 16 and 18), specifically during the transition from adolescence to emerging 
adulthood, described as the period of time between ages 18-29 (Arnett, 2014; Chen et al., 
2017; United Nations Office on Drugs and Crime 2018).  
Canadian research findings, like those in the USA, show that 4.9 million 
Canadians aged 15+ (~16%) reported using cannabis within the past three months 
(Statistics Canada, 2019).  Canadian data suggests a steady rate of use from the 3.1 
million users in 2013, 3.6 million users in 2015, and 4.4 million users in 2017 while 
considering population growth during this five-year period (Government of Canada., 
2017). Regional differences, however, suggest stronger trends towards increased usage, 
such that, Nova Scotia was found to be the highest using province in Canada (when 
sampling individuals over the age of 15; Statistics Canada, 2019), with 24.4% of Nova 
Scotians (vs. 16% of Canadians overall) reporting cannabis use in the past three months 
(Statistics Canada, 2019). Finally, usage rates proved to be on the rise with an increase in 
usage from 14% of Canadians to 18% between 2018 and 2019 (Statistics Canada, 2019). 
Furthermore, within the overall population of Canadian cannabis users, a quarter are 
between the ages of 15-24 years of age (Statistics Canada, 2019). Of the Canadian youth 
between the ages of 15-24, 24% were cannabis users, with 32% using daily, making this 
age category the most prevalent users (Government of Canada, 2017).  
Within cannabis users, differences also appear between males and females. Males 
reported higher usage rates (Cookey et al., 2020; Cuttler et al., 2016; Horwood et al., 
2010; Statistics Canada, 2019) and earlier usage when compared to females (Richmond-
Rakerd, Slutske & Wood 2017). This was also noted in a sample of grade 12 students, 
where daily cannabis users were more likely to be male (17%) than female (12%; 
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Johnston et al., 2011). The national cannabis study in Canada showed similar findings, 
reporting males were almost twice as likely to be cannabis users compared to females, 
especially within the 15-24-year-old age range (Statistics Canada, 2019). Moreover, 
males were more likely to be daily or almost daily users and were found to use cannabis 
for primarily non-medical reasons (52%); this percentage of non-medical use was over 
four times the non-medical use reported by females (Statistics Canada, 2019). Females 
were found to have an overall lower risk of becoming a cannabis user in the future 
compared to males when a predictive survival analysis was completed, factoring in 
several risk factors that could lead to substance use (i.e., age, ethnicity, use by age 17, 
Chen et al., 2017). The National Cannabis Use study in Canada found females (4.5%) to 
be significantly less likely to be daily or almost daily users of cannabis when compared to 
males (7.6%; Statistics Canada, 2019). Furthermore, females were also less likely to be 
weekly (1.7%) and monthly (1.3%) users compared to their male counterparts (5.4% and 
2.8% respectively; Statistics Canada, 2019). While there are sex differences in user 
profiles, it remains unclear if there are any differences in how cannabis affects the brains 
of males and females (see section 1.4 for full description of the known interactions to-
date between cannabis use and biological sex). 
1.3 Neurobiology of Cannabis Use 
Due to the overwhelming research showing cannabis usage is increasing not only 
in Canada but also worldwide, it is important that we understand the potentially negative 
consequences involved with the consumption of this drug. The uncertainty regarding 
what cannabis may do to the human brain and the behavioural impacts it may have has 
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influenced research to focus on measuring not only behavioural but also neurological 
changes in cannabis users.   
Past findings suggest cannabis users have decreased accuracy on tasks involving 
selective attention, behavioural inhibition, and decision making (Böcker et al., 2010; 
Crane et al., 2015; D’Souza et al., 2012; Galvez-Buccollini et al., 2012; Gruber & 
Yurgelun-Todd, 2005; Tibbo et al., 2018). The current state of the literature suggests 
there are mixed findings on how cannabis may impact executive functioning. While some 
studies report cannabis use is negatively associated with several neuropsychological 
impairments (i.e., attention, memory, and IQ scores) in those with cannabis use disorder 
(Camchong et al., 2017; Meier et al., 2012), other studies suggest cannabis users and non-
users do not differ on various indexes of cognitive decline (as measured by IQ; Jackson et 
al., 2016; Meier et al., 2018). A recent review and meta-analysis suggest that frequent and 
dependent cannabis use (by age 18) is associated with a decline in IQ scores compared to 
baseline; this may be restricted to a decline in verbal IQ while other aspects of IQ appear 
to be spared (see Power et al., 2020 for full review). Another review of longitudinal data 
suggests a more nuanced result where only the heaviest users are impacted and, in some 
cases, third variables (e.g., education, sex, parental income) account for the observed 
deficits in neuropsychological outcomes (see Gonzalez et al., 2017 for full review). 
Taken together these findings suggest that heavy, consistent use at a younger age may be 
more detrimental to IQ and other neuropsychological outcomes, whereas those with more 
casual later life use may not be impacted. Similar to discrepancies found in the IQ 
literature, studies measuring cannabis initiation in adulthood compared to adolescence 
(before age 17) show mixed findings. Earlier studies found cannabis use onset at a young 
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age was associated with decreased cognitive performance and attentional deficits 
(Ehrenreich et al., 1999; Pope et al., 2003), while more recent findings suggest deficits 
are only found in verbal working memory (Auer et al., 2016). These findings suggest that 
more research is needed to fully understand the association between early and 
frequent/consistent cannabis use and neuropsychological outcomes (i.e., memory, 
attention, IQ, and inhibition). 
Previous reports indicate that prolonged exposure to cannabis was associated with 
cognitive impairments compared to healthy controls or casual users (Pope & Yurgelun-
Todd, 1996). These impairments have been shown to be related to structural (Rocchetti et 
al., 2013) and functional (Pillay et al., 2008) changes in the brain, specifically in areas of 
the hippocampus (Hirvonen et al., 2012). Primarily, relationships have been found 
between cannabis use and decreased working memory and executive functioning in 
adolescents between the ages of 13-18 (Harvey et al., 2007). Adolescence and emerging 
adulthood are the peroids of time spanning the ages of 10 to 25 during which the human 
brain is developing and changing, including changes in neural connections (Arnett, 2014; 
Beckman, 2004; Cannon et al., 2005; Chambers et al., 2003; Nelson, 2004; Slotkin, 2002; 
Spear, 2000; Steinberg, 2014). During adolescence and emerging adulthood, many neural 
pathways are pruned to ensure there are efficient pathways in comparison to an 
abundance of neural connections (Bossong & Niesink, 2010; Cohen-cory, 2002; Katz & 
Shatz, 1996; Luna, 2009; Tibbo et al., 2018; Whitford et al., 2007). These alterations are 
driven by changes in grey and white matter within the brain (Tibbo et al., 2018). 
Camchong et al. (2017) found there was a decrease in functional connectivity between 
the caudal anterior cingulate cortex and the prefrontal cortex in adolescents diagnosed 
 15 
with a cannabis use disorder (CUD), suggesting that cannabis use is associated with this 
process.  
Structural changes have been documented through the use of magnetic resonance 
imaging (MRI) whereby researchers have shown decreases in grey matter volume and 
whole-brain volume in cannabis-using adolescents compared to healthy controls. 
Additionally, positron emission tomography (PET) revealed that males whose cannabis 
use onset occurred prior to age 17 not only showed decreases in the brain and grey matter 
volume, but also higher cerebral blood flow (Renard et al., 2014). Contrary to these 
findings, Moreno- Alcàzar et al. (2018) used whole brain voxel-based morphometry and 
found cannabis users and non-users did not differ on cortical regional differences or grey 
matter volume, instead they found that cannabis users had a significant cluster of 
increased grey matter volume in the basal ganglia  compared to non-users. While the 
current state of the literatre appears to be mixed on what structural changes occur with 
use, the current consensis appers to be that there are region specific volume changes 
associated with use.    
Past studies argued that chronic exposure to THC was neurotoxic for hippocampal 
neurons (in terms of a decrease in the overall volume of neurons; Scallet et al., 1987) 
causing hippocampal neuron dealth when THC interacted with the CB1 receptors (Chan 
et al., 1998), however, more recent reports suggest that cannabis use may not impact the 
hippocampus as it was once believed (Koenders et al., 2017; Moreno-Alcàzar et al., 
2018). These findings may allude to the fact that while THC alone (or in high quanities) 
may be neurotoxic, cannabis with a higher ratio of other cannabinoids (e.g., cannabidiol) 
may not impact neural functioning (i.e., hippocampal functioning) as much. Blest-Hopley 
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et al. (2019) examined if cannabis use impacted the metaboite markers of neurons and 
glia in the hippocampus and found altered myoinositol levels in cannabis users compared 
to non-users, however, the other metabolite concentrations (glutamate and N-acetyl 
aspartate) did not differ between groups. This suggests cannabis may only partially 
impact hippocampus. Further support for this can be found in Owens, Sweet and 
MacKillop (2019) where they found that only two regions of the hippocampus (head of 
the hippocampus and area CA1) were associated with recent cannabis use. Providing 
further clarity that while cannabis has been shown to impact the hippocampus, the effects 
cannabis has on the hippocampus may be restricted to certain areas and metabolites. 
While this suggests mixed findings on the potential risk of hippocampal damage due to 
cannabis use, this risk is potentially higher for individuals around the age of puberty who 
are using cannabis given the extent of the changes occuring in the brain during this time 
(O’Shea et al., 2004; Schneider & Koch, 2003, 2005). Cognitive functions such as 
focusing attention, inhibitory control, and filtering out irrelevant information have been 
shown to be negatively affected in heavy cannabis users compared to non-users and 
casual cannabis users (i.e., those using only once a month; Pope & Yurgelun-Todd, 1996; 
Solowij et al., 1991; Solowij & Michie, 2007).  Research has investigated the neural 
pathways that are at work during attention and emotional processing tasks in cannabis 
users and non-users; during these tasks, cannabis users appeared to be drawing upon non-
conventional neural networks to process this information (e.g., greater activation in the 
left middle and superior frontal gyrus), compared to the non-users (Colizzi et al., 2018). It 
was suggested that this reliance on alternative neural networks was to compensate for 
impairments in the standard brain networks and regions. This implies that while cannabis 
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may not impact entire neural structures (i.e., the hippocampus) it may impact one’s 
ability to properly use these cognitive areas to process and act on incoming stimuli as a 
non-user would. At a broader level, this suggests that cannabis may partially affect the 
neural pathways and connections within the brain influencing both behavioural and 
cognitive outcomes with heavy cannabis-using youth being most at risk. Unfortunately, 
many of these studies only include males and do not consider the effects of cannabis on 
the female brain.  
Furthermore, studies have shown that the dopamine system in the prefrontal 
cortex undergoes reorganization during adolescence (Bossong & Niesink, 2010; Spear, 
2000). Given the changes occurring in this system happen around the same time as the 
onset of cannabis use, use at a young age may impact this critical neurodevelopmental 
process, which could then result in deficits in decision making, inhibition, and planning 
behaviours. Adolescence and emerging adulthood may be especially vulnerable periods 
as changes in the prefrontal cortex at this age that may arise from early cannabis use 
could possibly cause irreversible changes later in life (Bossong & Niesink, 2010).  
Moreover, previous cannabis use has been shown to impact inhibitory functioning even 
after short peroids of abstinence (Solowij et al., 2002; Aharonovich et al., 2008; Cunha et 
al., 2010). This implies that the sensory processing pathways in the brain may be 
impacted even after the acute administration of cannabis. 
Cannabis use has been associated with several negative consequences, particularly 
as related to neuropsychiatric outcomes. Most notably is the potential relationship 
between early cannabis use and one’s risk of developing psychosis or schizophrenia later 
in life (Arseneault et al., 2002; Fergusson et al., 2003; Henquet et al., 2005; Mauri et al., 
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2006; Saito et al., 2013; Stefanis et al., 2004; Van Os et al., 2002; Weiser et al., 2002; 
Zammit et al., 2002). While genetic predispositions remain an important determinant in 
the development of psychosis/ schizophrenia, environmental factors are also at play (e.g., 
cannabis use or childhood trauma; Crocker & Tiboo, 2015; Renard et al., 2014; Tibbo et 
al., 2018). Multiple studies have found that age of cannabis use onset is negatively 
associated with psychosis, such that the age of first psychosis related hospitalization is 
earlier for those using cannabis (vs non-users) in individuals with no prior symptoms of 
psychosis (Arseneault et al., 2002; Galvez-Buccollini et al., 2012; Guloksuz et al., 2019; 
Henquet et al., 2005; Konings et al., 2008; Rubino & Parolaro, 2008; Stefanis et al., 
2004; Zammit et al., 2002). Not only has cannabis use been shown to correlate with 
psychosis, but it has also been shown that cannabis usage increases one’s risk of 
developing schizophrenia by 40% (Moore et al., 2007) or up to a 6-fold increase in heavy 
cannabis users (Saito et al., 2013). This relationship was shown to be impacted by the 
frequency of use, and potency of THC in the cannabis used with the more frequent users 
showing an increased risk of 5-200% (Smye, 2008) and higher potency of THC ( >10%) 
showing more than 4x’s an increased risk of psychosis (Di Forti et al., 2019). 
Furthermore, age of onset matters in this relationship: adolescents who used cannabis 
before the age of 15 increased their risk of being diagnosed with schizophrenia or related 
psychosis by 4.5 times, whereas those who used cannabis by the age of 18 were at only 
1.6 times increased risk (Arseneault et al., 2002; Murray et al., 2008). These studies 
reflect the increasing need to better understand the consequences cannabis has on neural 
functioning when used at a young age. 
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1.4 Impact of Cannabis Use in Males vs. Females 
MRI studies have been conducted to better understand brain development and 
potential sex differences in the changes that occur during development. There are robust 
findings showing that female neurodevelopment and mean cerebral volume peaks at 
around age 10.5 years while male development and cerebral volume do not peak until the 
age of 14.5 years (Lenroot et al., 2007). Additionally, longitudinal data have shown that 
subcortical structures and grey matter mature and change at different rates across 
adolescence depending on sex (Herting et al., 2019; Lenroot et al., 2007). Furthermore, 
studies mapping brain development trajectories suggest the prefrontal cortex may be the 
last brain region to mature during adolescent development (Gogtay et al., 2004; Lenroot 
and Giedd, 2006; Sowell et al., 2004). Given these brain development trajectories are not 
consistent across males and females, it is concerning that the age of critical 
neurodevelopment and the average age of onset of cannabis use intersect, this overlap 
may be particularly concerning for males given their later development (Herting et al., 
2019; Lenroot et al., 2007). Additionally, the brain areas undergoing the greatest 
developmental changes during these age-related growth phases (i.e., prefrontal cortex) are 
densely packed with CB1 receptors (Eggan & Lewis, 2007; Giedd et al., 1999; Lin et al., 
2009). The previously discussed differential rate of neurodevelopment in males vs. 
females also applies to the development of the frontal lobes (Lenroot et al., 2007). 
Furthermore, Lenroot et al. (2007) found that male brains showed a consistent and higher 
degree of change during childhood and adolescence than did female brains. A more 
recent meta-analysis (Ruigrok et al., 2014) suggests regional differences between sex 
such that males have larger volumes and higher tissue densities in a number of brain 
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regions (e.g., left amygdala, hippocampus, and putamen), this meta-analysis further 
suggests that males may have more left lateralized differences compared to females (see 
Ruigrok et al., 2014 for full review).  Therefore, males may be more vulnerable to the 
neurotoxic effects of cannabis as the average age of initiation occurs earlier during 
prefrontal neurodevelopment in comparison to females. It is, therefore, not surprising that 
recent reports show increased cannabis use was related to poorer decision making, but 
only among males (Gonzalez et al., 2012). While Gonzalez et al. (2012) found worse 
decision making in males, other researchers (Gillies & McArthur, 2010) found female, 
but not male, cannabis users (vs. non-users) experience poorer performance on measures 
of episodic memory; it has been suggested that this sex difference could be due to 
cannabis affecting estrogen-related dendritic spine maturation in the hippocampus among 
females.  Given these findings, it could be hypothesized that cannabis would 
differentially affect the brains of males and females, resulting in differing deficits 
depending on the cognitive processes under investigation.  Overall, however, we would 
expect males to be more heavily impacted by cannabis use as they are stereotypically 
more frequent, heavy users and past reports suggest they are more impacted by cannabis 
than their female counterparts on a greater variety of tasks. 
Most studies measuring sex differences in cannabis users measure the effects of 
cannabis on behavioural measures; however, these measures could be impacted by the 
psychomotor effects cannabis has on individuals (Crane, Schuster & Gonzalez, 2013; 
Felton et al., 2015; Herrman, Weerts and Vandrey, 2015). To truly understand the effects 
cannabis has on individuals and the sex differences that may be present, we must parse 
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apart the neural activity from the motor responses. To do so we can use tools like 
electroencephalography (EEG) and event-related potentials (ERPs). 
1.5 Event-Related Potentials (ERPs) 
EEG is a non-invasive procedure that measures the summation of the neural 
activity of large groups of neurons firing. ERPs are derived from EEG by assessing 
neuroelectric activity elicited in response to specific stimuli such as tones, visual stimuli, 
or internally generated processes such as decision making or inhibition. ERPs denote the 
average of the neural response following stimulus presentation. EEG raw data is averaged 
and small data sections, immediately following the event to be indexed, known as epochs, 
are isolated from the continuous EEG activity. These epochs are usually moments in time 
surrounding significant events such as stimulus onset or behavioural response. In order to 
obtain the ERP, multiple epochs are averaged to eliminate any concurrent electrical noise. 
Usually, ERPs are recorded during the performance of behavioural tasks, and the data 
collected from both behavioural measures and the EEG recording can be used to form the 
complete picture of the cognitive processes at work during particular situations or tasks. 
ERPs are well suited to index cognition due to their temporal sensitivity and can be used 
to help supplement and comprehend behavioural observations. 
The ERP waveform is plotted with voltage measured in microvolts (µV) against 
time measured in milliseconds (ms). The waveform appears as a sequence of positive (P) 
and negative (N) peaks and deflections which are characterized and labeled in terms of 
the latency or succession in which they appear. Mid-latency auditory-evoked responses 
(MLAER: Lijffijt et al., 2009) are a series of ERPs commonly used to measure pre-early 
and late attentive phases of sensory gating-related information. Sensory gating is 
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conceptualized as the brain’s ability to inhibit or ‘gate-out’ extraneous information from 
being processed by the brain (Broyd et al., 2013; Freedman et al., 1991), allowing the 
brain to focus and allocate attentional resources on relevant incoming information and 
thereby avoiding overload (Evans & Drobes, 2009). The MLAER is comprised of the 
P50, N100, and P200 ERPs. While the MLAERs rely on auditory stimuli to be measured, 
there are other ways to measure inhibition; specifically, this can be done by examining 
the Go/NoGo P300 described later. 
1.5.1 Mid-Latency Auditory-Evoked Responses (MLAER) 
While the pre-attentive P50 is the most studied marker of sensory gating, there 
has been a growing body of literature reporting that early and later attentive phases of 
sensory gating-related information processing can be captured by the N100 and P200 
components of the MLAER, respectively (Boutros et al., 2004; Lijffijt  et al., 2009; Shen 
et al., 2020; Zabelina et al., 2015). Recent studies show the N100 and P200 can be 
utilized as neurophysiological markers of sensory gating due to their superior reliability 
compared to the P50 (Anokhin et al., 2007; Boutros et al., 2019; Rentzsch et al., 2008; 
Shen et al., 2020; Thoma et al., 2020). While these three components are related, they 
appear to index different neural processes (Boutros et al., 2004; Sklar and Nixon 2014). 
The P50 appears to reflect pre-attentional inhibitory filter mechanisms and sensory 
gating, while N100 gating has been suggested to index filter mechanisms involved in 
attentional triggering (Wan et al., 2008), and P200 gating might index filter mechanisms 
involved in attentional allocation and early conscious awareness of a stimulus (Chien et 
al., 2019; Lijffijt et al., 2009; 2011).  
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 N100 and P200 gating may reflect protective neural mechanisms that shield 
cognitive function through interactions with working memory processes to enhance target 
discrimination (Lijffijt et al., 2009). A series of replication studies have shown P50 
suppression to be reduced in chronic cannabis users who were medically and 
psychiatrically healthy and did not abuse any illicit substances other than cannabis, with 
the greatest reduction in P50 suppression observed in those with the greatest cannabis 
exposure (Broyd et al., 2013; Edwards et al., 2009; Patrick et al., 1999; Patrick & Struve 
2000; Rentzsch et al., 2007). To date, only one study has measured the effects of cannabis 
on N100- and P200-indexed sensory gating (Francis et al., 2021). This study from our lab 
found that gating was inhibited in cannabis users compared to non-users (Francis et al., 
2021). Of interest, this study found no deficit in P50 amplitudes in cannabis users relative 
to non-cannabis-using controls. 
This inhibitory process can be shown through the MLAER in response to paired 
tones (Freedman et al., 1991). In a paired click paradigm, commonly used to measure the 
MLAERs, a pair of tones are presented to participants; the first tone (S1), considered to be 
the conditioning tone, is presented with an identical second tone (S2) being presented 500 
ms after (Boutros & Belger, 1999; Broyd et al., 2013). The MLAERs typically display a 
reduction in amplitude when a second click (S2) is presented approximately 500ms 
following the preliminary click (S1; Turetsky et al., 2007). It has been shown that with 
healthy individuals there is a decrease of approximately 80% in the second P50 wave in 
comparison to the first; it is believed that this is due to the brain’s activation of the 
inhibitory network following the conditioning stimuli (Braff & Light, 2004; Broyd et al., 
2013). Due to the presence of MLAERs in response to both the S1 and S2 (Braff & Light, 
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2004), researchers have used this to quantify the brain’s sensory gating ability, in the 
form of a ratio (i.e., the amplitude of the response to S2  divided by the amplitude of the 
response to S1 (S2/S1; Smith, Boutros, & Schwarzfopf, 1994)). Though less often used, 
sensory gating can also be quantified as the difference between the P50 amplitude elicited 
by S1 and S2 (i.e., S1-S2; Smith et al., 1994). This latter measure has been suggested to be 
more reliable than the ratio (Smith et al.,1994; Turetsky et al.,2009). Lower ratios or 
larger differences represent a better ability to inhibit extraneous information for all three 
MLAERs (Boutros & Belger, 1999).  
The neural circuitry responsible for this process of inhibition has been reported to 
involve the hippocampus and hippocampal structures (Waldo et al., 1994), specifically 
arising from the inhibitory interneurons located in the hippocampus (Freedman et al., 
1991). Of particular interest is the fact that these hippocampal brain areas also have a 
significant distribution of CB1 receptors – specifically in the dentate gyrus which projects 
to CA3 (Herkenham et al., 1990; Li et al., 1994). Furthermore, the hippocampus appears 
to be particularly vulnerable to the long-term effects of cannabis use. One study 
measuring the CB1 receptor density in cannabis users found that all brain areas showing 
downregulation of CB1 receptor density returned to normal after an abstinence period of 
approximately one month with the exception of the hippocampus (Hirvonen et al., 2012). 
Due to the neural generators of the P50 being located in the hippocampus (Freedman et 
al., 1991; Waldo et al., 1994), this suggests chronic cannabis users would be expected to 
have reduced P50-indexed sensory gating. Such results have been shown in chronic 
cannabis users, who showed significantly higher sensory gating ratios (i.e., worse gating) 
compared to non-using controls (Broyd et al., 2013; Patrick et al., 1999). Further research 
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looked at how sensory gating was affected by cannabis use in adolescence; the same 
pattern of high gating ratios were present in adolescent cannabis users (vs. non-users), 
where increased THC use was associated with a decreased ability to inhibit sensory 
information (Patrick & Struve, 2000). Furthermore, the degree to which sensory gating is 
impacted is relative to the individual’s daily consumption rate or the number of joints 
smoked, indicating the more cannabis one uses the more one’s sensory gating is impacted 
(Edwards et al., 2009; Patrick et al., 1999; Rentzsch et al., 2007). Of concern is that these 
studies did not consider biological sex when measuring these impacts. This gap in the 
literature is concerning given previously discussed sex-based differences in 
neurodevelopment relative to the average age of first cannabis use and the predominance 
of male cannabis users. 
While all three ERP components are said to measure sensory gating (i.e., P50, 
N100, P200), they are not all generated by the same brain structures. This suggests that 
one component could be impacted while the others are spared, as was shown in the first 
published study measuring all three MLAER components in individuals with 
schizophrenia (Freedman et al., 1983). The N100 is a negative-going waveform occurring 
roughly 100ms post stimulus presentation. The N100 is generated for auditory stimuli 
suggesting its link with the auditory cortex (Ren et al., 2021). Prior research has shown 
that individuals with schizophrenia present with reductions in N100 amplitude (Connolly 
et al., 1985; Iwanami et al., 1994; O’Donnell et al., 1994; Shelley et al., 1999). This has 
since been linked to a deficit in bottom-up auditory sensory-perceptual processing (Ren et 
al., 2021). In addition, it has been suggested that attentional factors play a role in the later 
components (N100/P200) suggesting active attention could impact the expression of 
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these components (Boutros et al., 1999). Other work has since verified this by indicating 
that selective attention can increase N100 amplitudes (Hackley et al., 1990; Hillyard et 
al., 1973; Näätänen et al., 1981; Woldorff, Hackley and Hillyard 1991). It has, therefore, 
been suggested that the N100 is a reliable measure of sensory filtering when the ratio of 
S2/S1 is used (Fuerst et al., 2017; Rentzsch et al., 2008) while P200 is a measure of early 
attentional processing (Näätänen et al.,1992). 
1.5.2 Visual Evoked Potentials (VEP) 
The P100 is a measure of primary visual cortex activity that is elicited by any 
visual stimulus to which an individual attends. It has a peak amplitude at roughly 100-
130 ms post-stimulus presentation (Luck, 2014). The P100 has been suggested to be an 
index of early attentional processing occurring in the primary visual cortex (Mangun 
1995; Mangun & Hillyard 1990). It has been shown to present differently in males and 
females, with females showing increased amplitudes compared to males (Sharma et al., 
2015). To date, only one study has examined the P100 in cannabis users; this study 
examined the effects of the administration of oral THC in two groups of cannabis users: 
occasional and heavy users (Theunissen et al., 2012). They found that there was a 
decrease in P100 amplitude for occasional users when THC was administered relative to 
a placebo control condition; however, the opposite was true of heavy users where an 
increase in P100 amplitude was shown (relative to placebo control; Theunissen et al., 
2012). However, the decrease in occasional users was significantly different from their 
placebo control whereas the increase in heavy users’ P100 amplitude was not, suggesting 
the P100 was impacted by THC administration more in occasional users than heavy users 
(Theunissen et al., 2012). 
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Another more commonly studied VEP is the visual P300 ERP. The P300 is an 
index of CNS activity that reflects one’s ability to process incoming information and 
incorporate it into a memory trace of the given stimuli or the context for which the 
stimuli are presented (Polich & Herbst, 2000). Additionally, P300 latency is known to 
represent the processing time required by an individual before being able to generate a 
response, therefore classifying P300 as a measure of neural activity that underlies 
attentional resources and immediate memory (Polich & Herbst, 2000). Due to the nature 
of P300, it has been found that any brain disorder that alters the primary cognitive 
operations of attention allocation and immediate memory will show an effect in P300 
amplitude or latency – or both (Polich & Herbst, 2000). Changes in P300 amplitude (i.e., 
decreased amplitude, maximal amplitude shifts more posteriorly for participants with 
schizophrenia who are unmedicated) have been shown in individuals diagnosed with 
depression and schizophrenia (Boutros et al., 1997; Bruder et al., 1995; McCarley, Faux, 
Shenton, Nestor, & Adams, 1991). The P300 waveform is characterized as a large 
positive-going waveform that occurs approximately 300 ms post-stimulus presentation 
(Gray et al., 2004). This ERP arises when higher-order cognitive processes are at work, 
specifically those involved with attentional resources (Donchin & Coles, 1988). It has 
been found that the amplitude of the P300 ERP is proportional to the degree of attentional 
resources dedicated to processing said stimuli; therefore, the more resources that are 
used, the higher the P300 amplitude (Duncan-Johnson & Donchin, 1977). Notably, the 
term P300 refers to a series of related but different positive-going waveforms, including 
the NoGo P300 that has been shown to represent behavioural inhibition on particular 
tasks (Falkenstein et al., 1999; Polich, 2007; Salisbury et al., 2004). 
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The Go/NoGo paradigm has been used to address response inhibition. This 
paradigm measures one’s ability to inhibit a response during a sequence of stimuli. The 
Go/NoGo task has two responses required by participants: perform a behavioural 
response (e.g., click a mouse) if the trial is a ‘Go’ trial or inhibit this response if the trial 
is a ‘NoGo’ trial.  The majority of trials are Go trials, which makes it more difficult for 
participants to inhibit responses. Conversly, NoGo trials require participants to inhibit a 
prepared response, indexed through the P300 ERP (Salisbury et al., 2004). The NoGo 
P300 has been reported to be reflective of the activation of frontal networks with little 
activation of the parietal cortex; conversly, the Go P300 reflects increased activation of 
the parietal cortex compared to the frontal networks (Laurens et al., 2005; Salisbury et al., 
2004). The NoGo stimuli activate frontal areas of the brain that coincide with the 
distribution of the inhibitory network, also located in the frontal cortex (Nash, Schiller, 
Gianotti, Baumgartner, & Knoch, 2013; Salisbury et al., 2004). This is measured as a 
positive waveform occurring approximately 300 ms following the NoGo stimulus, with a 
fronto-central maximum.  
Similar to the sex differences observed with the MLAERs, the NoGo P300 also 
exhibits sex differences (Melynyte et al., 2017). It was found that females took longer to 
respond and displayed larger P300 amplitudes on NoGo trials relative to males (Melynyte 
et al., 2017). Additionally behavioural differences between sexes have been shown, 
suggesting males are more accurate in responding to Go trials than females however, the 
same was not true for the NoGo trials whereby groups did not differ (Melynyte et al., 
2017). This finding suggests that females allocate more resources to inhibiting the 
response to the NoGo trials (Melynyte et al., 2017). Additionally, other studies have 
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reported P300 amplitudes correlated with parietal lobe grey matter volume independent 
of body and brain size (Sowell et al., 2007). These observed differences in parietal lobe 
grey matter are in accordance with the recent findings of sex differences in NoGo P300 
latency and amplitude (Melynyte et al., 2017) given females have been found to have 
thicker temporal and parietal cortices compared to males (Sowell et al., 2007). Moreover, 
hormone levels influence latency times for females on the NoGo task. For example, it 
was found that progesterone levels negatively correlated with NoGo responses (i.e., 
higher progesterone levels were correlated with shorter latencies on the NoGo task; 
Galvez-Buccollini et al., 2012). This finding is consistent with reports that progesterone 
has neuroactive metabolites that modulate the transmission of GABA, which in turn 
activates the dopamine system (Barth et al., 2015). Seeing as the NoGo response is 
dependent on dopamine and serotonin, it is not surprising that a change in progesterone 
would affect these responses (Galvez-Buccollini et al., 2012).  
In addition to the observed sex differences on the NoGo P300, different 
recreational substances such as cannabis can affect this ERP as well. This is not 
surprising, considering the distribution of CB1 receptors in the frontal networks and the 
frontal neural networks involved in the generation of the NoGo P300 ERP. It was found 
that administration of small levels of THC (3.45%) decreased the NoGo P300 amplitude 
(Ilan et al., 2005). This suggests that even low dosages of THC in cannabis can exert 
acute negative impacts on inhibitory systems and therefore, the NoGo P300. 
Similar deficits in NoGo P300 amplitude have been found in those with cannabis 
use disorder (CUD) suggesting inhibitory functioning is not only impacted by acute use 
but also by heavy consistent use. Individuals with CUD had significantly reduced NoGo 
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P300 amplitudes compared to non-using controls (Maij et al., 2017). Furthermore, CUD 
individuals took longer to respond to Go trials, although amplitudes were unaffected; this 
was theorized to be due to a speed-accuracy tradeoff whereby cannabis users try to to be 
correct in their response and therefore, must decrease the speed at which they can respond 
to allow for adequate processing time (Maij et al., 2017). Spronk, De Bruijn, van Wel, 
Ramaekers, and Verkes (2016) found similar results on the NoGo task where cannabis 
users showed decreased amplitude on the NoGo P300 ERP, with prolonged latencies 
shown as well compared to non-users. In addition, cannabis users had impaired 
behavioural response inhibition and increased errors during the NoGo task (Spronk et al., 
2016). Exploratory analysis showed that the frequency of cannabis use was positively 
associated with the slowing of responses (Spronk et al., 2016). These findings need be 
interpreted with caution however, given that these participants were polydrug users using 
not only cannabis but also cocaine on a yearly basis (i.e., cocaine use more than 5 times 
in the past year; Spronk et al., 2016) indicating it may be the combination of drug use that 
impacts behavioural inhibition.  While the frequency of cannabis use has been shown to 
impact inhibition and response times, other studies have measured THC quantity in the 
cannabis strain and how the acute effects of cannabis may be dose-dependent. Hunault et 
al. (2009) found that as the concentration of THC increased, participants’ response time 
slowed down, motor control worsened, and the number of errors made increased, along 
with a concurrent decline in short-term memory and sustained attention. These results 
suggest that these effects are not uniform across cannabis strains, but are dependent on 
the dosage of THC consumed. Moreover, the effects on cannabis users may vary 
depending on biological sex. These factors, however, are rarely taken into consideration 
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when discussing cannabis use. In fact, females are typically not included in cannabis 
research and, if included, differences between biological sex are often not tested or 
discussed. Moreover, no study to date has measured the interaction of sex and cannabis 
use on the NoGo P300.  
1.6 The Current Study  
The current study was originally designed to address gaps in the literature by 
assessing the potential differences in cannabis-related deficits in neural functioning 
between males and females. Unfortunately, due to an insufficient sample size, this 
moderation analysis was not possible. A secondary goal of this study was to better 
understand the main effects of : 1) cannabis use (users vs. non-users), and 2) biological 
sex (males vs. females), on ERP measures of sensory gating and inhibitory processing. 
Hypothesis 1: With prior work showing cannabis users have decreased amplitudes 
to inhibitory stimuli (Broyd et al., 2013; Edwards et al., 2009; Francis et al., 2021; Ilan et 
al., 2005; Maij et al., 2017; Patrick et al., 1999; Patrick & Struve 2000; Rentzsch et al., 
2007; Spronk et al., 2016), we hypothesized that cannabis users would show reduced 
amplitudes in all ERP indexed measures of cortical inhibition (MLAERs and NoGo P300 
amplitudes) compared to the non-using controls.  
Hypothesis 2: While there has been limited research done regarding sex 
differences within the chosen paradigms the research that does exist suggets females have 
larger NoGo P300 amplitudes and longer latencies relative to males (Melynyte et al., 
2017). For this reason we hypothesized that there would be larger NoGo P300 amplitudes 
and longer latencies (NoGo P300) in females compared to males. Given the limited 
research surrounding sex differences in the MLAER, this latter analysis was exploratory.  
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Hypothesis 3: Based on the ehanced visual cortex processing in cannabis users 
shown by Theunissen et al. (2012), it was hypothesized that we would see increased P100 
amplutudes in CUs compared to NUs. The analyses of biological sex (males vs. females) 
effects on P100 amplitude were exploratory. 
Hypothesis 4: Finally, while age of first use has been not found to correlate with 
sensory gating, sensory gating deficits have been shown to correlate with the number of 
years with consistent consumption (Rentzsch et al., 2007). With these findings in mind, 
we anticipated that cannabis users with more years of consistent use would show deficits 
on indexes of sensory gating. We also anticipated that number of years of daily (or almost 
daily) cannabis use would correlate with the Go/NoGo behavioural inhibition measures 
such that higher years of consistent cannabis consumption would be associated with 





Chapter 2: Paired Click Paradigm 
2.1 Participants 
 Individuals (N = 30) between the ages of 18-30 years were recruited from the 
local community, including 14 regular cannabis users (CU; 9 males, 5 females) and 16 
cannabis non-using controls (NU; 4 males, 12 females). CUs were defined as individuals 
who used cannabis 3 or more times a week at the time of study entry, with this rate of 
usage maintained for at least six months prior to participation (James et al., 2011). NUs 
were those who had used cannabis less than 10 times in their lifetime, with no use in the 
past year (James et al., 2011). Thirty years old was chosen as the upper limit due to 
changes in circulating estrogen levels that initiate at approximately age 30 in females that 
may confound our data (Musey et al., 1987). Additionally, this age captures the emerging 
adult age range (18-29 years) allowing us to focus in on specific cognitive changes that 
may take place in this critical developmental phase (Arnett, 2014). 
Demographic and health information was disclosed through a series of questions 
posed during a screening session to establish eligibility to participate. Participants ranged 
in age from 19-26 years (M = 21.6; SD = 2.21; see Table 1 for full demographic 
information). All female participants had a regular length menstrual cycle (i.e., 
approximately 28 days, Wilcox, Dunson & Baird 2000) and were not using any 
medications that could alter sex hormones (e.g., oral contraceptives) at the time of the 
study. All female participants were required to be nulliparous and not currently pregnant 
to minimize the influence of the hormonal changes caused by prior and current pregnancy 
(Cost et al., 2014; Walia, Aggarwal & Wadhwa 2013). All participants were required to 
be right-handed, as determined by a handedness inventory to ensure source localization 
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during analysis (Oldfield, 1971). Participants were required to have normal or corrected-
to-normal vision and normal hearing, as determined by self-report, to ensure these were 
not confounds to the study. To measure sex as a biological variable, participants were 
asked to self-disclose their sex; sex was defined to our participants as their biological sex 
at birth, which is generally divided into two categories: male and female. Finally, it was 
mandatory that participants could read and understand both spoken and written English 
for the purposes of the informed consent procedures and self-report measures.  
Written informed consent was obtained prior to testing during the in-lab session. 
This study was approved by the Research Ethics Boards of the Nova Scotia Health 
Authority ROMEO file #1024305, Saint Mary’s University Research Ethics Board #21-
007, and Mount Saint Vincent University Research Ethics Board #2018-190. 
2.1.1 Exclusion Criteria  
 Participants were excluded if they met any of the following criteria: diagnosis of a 
DSM-5 disorder, apart from cannabis use disorder (CU group only); a history of head 
injury with diagnosed concussion or loss of consciousness within the past six months; 
diagnosis of epilepsy or any other form of neurological disorder; current or regular use of 
psychoactive medication (other than cannabis); or diagnosis of a learning disorder. All 
exclusion criteria were assessed during a screening call where participants were asked to 
self-report this information. 
2.2 Study Procedure 
 To determine eligibility, participants completed a screening procedure over the 
phone. Following this, eligible volunteers were each invited to attend an in-person 
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laboratory session where they participated in a battery of neurophysiological tests. All 
testing sessions took place between 8 am and 11 am to control for circadian fluctuations 
in alertness and EEG patterns throughout the day (Hines, 2004). All participants were 
required to abstain from drug use (including cannabis, tobacco, and alcohol, any 
medication that can alter neurological functioning, and caffeine) beginning at midnight 
the night before EEG recording.  
2.3 Questionnaires   
To better understand participants’ overall substance use patterns, several validated 
questionnaires were administered. The Alcohol Use Disorders Identification Test 
(AUDIT; Bohn et al., 1995; Saunders et al., 1993) was administered by a trained 
researcher to every participant to quantify risky alcohol consumption, as well as risk 
factors correlated with alcohol use and dependency. The AUDIT uses a mix of three and 
four-point scales to classify individuals into one of four categories (abstinence, low-risk 
consumption, hazardous/harmful level, high risk for dependence) based on how risky 
their drinking behaviours are. Questions one through eight on the AUDIT are scored on a 
five-point scale (0-4) while questions nine and ten are scored on a three-point scale (0, 2, 
4) (α = 0.82). Scoring protocols were obtained from Saunders via the following link 
https://auditscreen.org/about/scoring-audit/. Scores range from 0-40 where 0 represents 
abstinence and no issues with alcohol use. A score ranging from 1-7 indicates low risk 
consumption, while scores ranging from 8-14 suggest hazardous levels of alcohol 
consumption. Finally, scores exceeding 15 indicate likelihood of alcohol dependence. All 
scoring was completed by a trained research assistant with higher scores indicating more 
hazardous drinking behaviour. Additional information on alcohol use, as well as 
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information regarding nicotine and cannabis use, was gathered through the administration 
of the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST, WHO 
ASSIST Working Group, 2010). The ASSIST is a validated measure used to identify 
substance misuse and related issues. The ASSIST is used in research to gather 
information on a wide range of commonly used substances and was used in this study to 
help identify any potential confounds between cannabis use groups. The ASSIST is an 
eight-item measure where participants were asked to indicate with the selection of yes or 
no which substances they have used in their lifetime (e.g., Cannabis, alcohol, inhalants, 
opioids). The remaining seven questions were follow-up questions to gather more 
information on substance use. Participants were asked to indicate how many times over 
the past three months they had used the substances for which they indicated previous use, 
as well as questions regarding how the substances affected their health and social life, and 
how their substance use may have impacted their productivity. Questions two through 
eight were answered on a four-point scale; higher numbers indicate a need for 
intervention level (i.e., indexing problematic use).  
Participants who disclosed regular cannabis use (i.e., all CU’s), were given the 
Reasons for Substance Use Scale (ReSUS; Gregg et al., 2009) to assess their motivations 
behind using cannabis. This is a 38-item measure using a four-point scale (0 = never; 3 = 
almost always) that assesses three common reasons for use: 1. Coping with distressing 
emotions and symptoms (18 items; Cronbach’s α= 0.91; e.g., “when I am feeling 
depressed”, “when I am feeling stressed” and “when I hear sounds or voices other people 
can’t hear”); 2. Individual enhancement (11 items; Cronbach’s α = 0.81; e.g., “when I 
want to chill out or relax”, “when I want to feel drunk, stoned or high” and “when I want 
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to fit in with other people”); and 3. Social enhancement and intoxication (9 items; 
Cronbach’s α = 0.82, e.g., “when I want to feel more self-aware”, “when I need 
motivation to do things” and “When I want to feel normal”).  Scores on each question are 
totaled to generate subscale totals; higher scores indicate more likely use for the indicated 
reason; these were reported in descriptive statistics as well as used for the correlational 
analysis. 
To assess differences in cannabis strains, any participant that identified as a 
cannabis user was asked to answer self-report questions on an author-generated measure 
regarding the THC:CBD content of their preferred strain to the research team, along with 
information concerning the frequency of use and the duration of consistent cannabis use 
(in years). 
2.4 EEG Recording and Computation  
Electrical activity was recorded from a BrainVision 64-channel electrode cap with 
Ag+ /Ag+ Cl- ring electrodes (Brain Products GmbH, Gilching, DE). Electrodes were placed 
on all 64 scalp sites using the 10-20 system of electrode placement, including three 
midline sites (frontal [Fz], central [Cz], parietal [Pz]), three left hemisphere sites (frontal 
[F3], central [C3], parietal [P3]), and three right hemisphere sites (frontal [F4], central [C4], 
parietal [P3]). Electrodes were also placed on the nose to serve as reference channels, 
while left and right mastoid were built into the cap at site TP9 (left) and TP10 (right) and 
were used to serve as the offline reference channels. Electro-oculogram activity was 
recorded from external canthi sites via bipolar channels; additional supra-orbital electro-
oculogram activity was captured by site FP1 (left eye) and FP2 (right eye). All electrode 
impedances were kept below 5 kW and all electrical activity was recorded using 
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BrainVision Recorder software and a BrainVision ActiCHamp amplifier (Brain Products 
GmbH, Gilching, DE) with an amplifier bandpass of 0.1 and 30Hz digitized at 500 Hz. Data 
was stored on a hard drive for offline analysis using the BrainVision Analyzer software. 
All data was re-referenced offline to the mastoid channels (TP09, TP10) before being 
digitally filtered, and segmented based on the paradigm (i.e., Paired click paradigm, and 
Go/NoGo).  
2.5 Test battery 
The paired click paradigm used a series of sixty-four paired clicks (S1-S2) 
presented to participants at a sound level of 80 dB while they fixated on a silent movie 
(i.e., Disney’s Fantasia) presented in front of them. Clicks were separated with an inter-
click interval of 500 ms and an intrapair interval of 8 seconds. Tones were presented 
binaurally through Etymotic 3C in-ear headphones (Etymotic Research, Inc., Elk Grove 
Village IL). This paradigm follows well-established procedures (Boutros & Belger, 1999; 
Knott et al., 2009; Rentzsch et al., 2007; Zouridakis & Boutros, 1992) to elicit three 
components of the MLAER: the P50, N100, and P200, all of which have a maximal 
amplitude at scalp site Cz.  
2.6 ERP analysis  
To analyze each component, data was segmented separately into the 1st (S1) and 
2nd (S2) clicks. Both S1 and S2 were segmented from -40-110 ms relative to the onset of 
the click. For the P50 analysis, electrical epochs were then digitally filtered using low and 
high filters of 10-50 Hz respectively, to increase the signal-to-noise ratio. The N100 and 
P200 were analyzed within epochs of 400 ms duration (including 50 ms pre-stimulus) 
using a frequency filter ranging from 0.1-30 Hz. All epochs were then ocular corrected 
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for eye movement (residual movement and blinks) using the Gratton and Coles algorithm 
(Gratton, Coles & Donchin, 1983) and baseline corrected (relative to the 0 ms pre-
stimulus segment). Epochs containing voltages above 50 μV were excluded from the 
analysis and the remaining data was used for the final ERP averaging.  
Taken from the Cz scalp site, the site of maximal amplitude, P50 amplitudes were 
measured as the amplitude of the most positive peak from 40-80 ms relative to click 
onset. Peak picking was done using the averaged waveforms for each participant using a 
semi-automatic process with each peak verified by the first author AMF. To ensure 
accurate detection of the P50, additional constraints were applied to the analysis protocol  
(Nagamoto et al., 1991; Zouridakis & Boutros, 1992): the P50 had to be observed in at 
least one of the other central electrode sites (C3 and C4), and S2 P50 activity must peak 
within 10 ms of the peak observed from the P50 of S1. The N100 was defined as the 
largest negative deflection between 80 – 180 ms while the P200 was defined as the 
largest positive deflection between 100 and 250 ms (Gooding  et al., 2013). Latency (time 
to reach peak P50 amplitude from stimulus onset) was derived for S1 and S2 of each 
component (P50, N100, P200). Latency scores were generated during the semi-automatic 
peak picking processes and were taken from the averaged waveform for each participant 
at the site of maximal amplitude (i.e., Cz). 
For each component, we calculated sensory gating in two ways following Broyd 
et al. (2013): to facilitate comparisons between past cannabis research (Edwards et al., 
2009; Patrick  et al., 1999; Rentzsch  et al., 2007), gating ratios (S2/S1) for each 
component (i.e., rP50, rN100, rP200:  S2/S1) were generated. Difference measures (S1 – 
S2) of sensory gating have been used more recently (Broyd  et al., 2013; Edwards  et al., 
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2009; Rentzsch  et al., 2007; Smith  et al., 1994; Turetsky  et al., 2009) to provide a more 
reliable index of sensory gating. Accordingly, we also calculated difference scores for 
each component (i.e., dP50, dN100, dP200).  
2.7 Behavioural analysis 
There is no behavioural data for the paired-click task as it is a passive listening 
task. 
2.8 Statistical analysis  
Two mixed analyses of variances (ANOVA) were conducted for P50 amplitudes 
using the Statistical Package for the Social Sciences (SPSS; IBM Corp., Armonk, NY), 
the first with one between-groups factor (2 levels: CU and NU) and one within-groups 
factor (2 levels: Stimulus one (S1) and Stimulus two (S2)). The second mixed ANOVA 
included one between-groups factor (2 levels: Male and Female) and one within groups 
factor (2 levels: Stimulus one (S1) and Stimulus two (S2)); this analysis also included 
weekly cannabis consumption as a covariate to account for any confound sex differences 
in cannabis use may bring to the analysis. For the sex-based analysis, estimated marginal 
means and standard errors were reported to account for the impact of our covariate in the 
analysis.  
 In addition, the amplitude values for each stimulus were used to calculate both 
gating ratio (rP50:  S2/S1 x 100) and difference (dP50:  S1 – S2) indices. Two separate 
univariate ANOVAs were performed with gating ratio (rP50) and gating difference 
(dP50) scores as dependent measures. The first included cannabis use (CU and NU) as a 
fixed factor, while the second used sex (Male and Female) as a fixed factor. For the 
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analysis of sex on gating ratio and difference scores, weekly cannabis use was added as a 
covariate in the analysis as was done for P50 amplitudes.  
These same processes were carried out for the other components of the MLAER 
(i.e., N100, P200) with the exception of the ratio and difference scores which were only 
carried out for the N100 consistent with prior research conducted in our lab (Francis et 
al., 2021). Non-significant F-test parameters are reported in Tables 3-6. These values are 
only reported in text when significant (i.e., p < .05) or at the non-significant trend level 
(i.e., p =.07 - .05).  
Latency was calculated as the time to reach peak amplitude from stimulus onset; 
latencies were generated for S1 and S2 separately for each of the three ERPs of interest. 
Additional mixed ANOVAs were computed to assess influences on latency for each of 
the three ERPs of interest with one between-groups factor, cannabis use (2 levels: CU, 
NU) and one-within groups factor, stimuli (2 levels: Stimulus 1 Latency (S1), Stimulus 2 
Latency (S2)). An additional mixed ANOVA was run to address the potential impact of 
sex; this ANOVA had one between-groups factor, sex (2 levels: Males and Females) and 
one-within groups factor, stimuli (2 levels: Stimulus 1 Latency (S1), Stimulus 2 Latency 
(S2)) with a covariate of weekly cannabis use. 
 Latency was used to assess differences between cannabis use groups and between 
male and female participants. Latency was defined at the time to reach peak amplitude for 
each of the three MLAER components of interest for both S1 and S2 trials. As with 
amplitudes, non-significant F-test parameters are reported in Tables 3-6. These values 
were only reported in text when significant (i.e., p < .05) or at the non-significant trend 
level (i.e., p =.07 - .05).  
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A priori planned comparisons involving cannabis use and sex were examined for 
neurophysiological outcomes (i.e., amplitudes and latencies) in regions of maximal 
amplitude. All marginal interactions were probed as it takes more power to detect an 
interaction effect, than a main effect. All analyses were accompanied by effect size 
calculations due to our small sample size. We used Hedges’ g (a corrected version of 
Cohen’s d) to calculate effect sizes due to our uneven sample sizes (Lakens, 2013). Effect 
sizes were interpreted the same as Cohen’s d: g = .2 represents a small effect, g = .5 
represents a medium effect, and g = .8 represents a large effect (Lakens, 2013).  
Finally, a bivariate correlational analysis was conducted using a two-tailed 
significance level to analyze correlations between demographic variables, questionnaires 
(AUDIT, ASSIST), and ERP data (amplitude and latency).  
Power analyses were conducted separately for each component (P50, N100 and 
P200) to determine observed power (post-hoc analysis; see section 2.9 for outcome of the 
power analysis), the statistical test used was an independent samples t-test as this would 
allow sufficient power to detect differences between groups (i.e., cannabis conditions and 
sex). Two tailed tests with the following effect sizes (P50: small d = .42), N100- small (d 
= .13); and P200- small (d = .43)) were used along with the appropriate group size (i.e., 
CU vs. NU analysis: n = 14, n = 16; Sex based analysis: n = 13, n = 17). A priori analyses 
were also conducted using the independent samples t-test as the statistical test, all while 
maintaining 80% power. Effect sizes for the P50 power analysis were based off 
(Rentzsch et al., 2007, 2017), while the N100 effect sizes were based off prior work in 
our lab (Francis et al., 2021). Due to the novelty surrounding the P200 ERP we were 
unable to conduct an a priori power analysis. 
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2.9 Paired click paradigm power analysis  
The observed power for between groups (CU vs NU) differences for the paired 
click P50 amplitude was 20% power, suggesting we would need a sample size of 84 
participants per group to observe differences at an 80% power threshold. Power analysis 
was also computed for the N100 and suggested we had an observed power of 6% with a 
sample size of 144 per group necessary to observe differences at 80% power. We had an 
observed power of 20% for the P200; no a priori power analyses were able to be 
completed with the novelty in this area and no effect sizes could be generated from prior 
papers. Given these are larger than normal sample sizes for ERP studies, this suggests 
there are no differences between groups.  
2.10 Results  
All 30 participants (CU = 14; NU = 16) were included in the analysis of the paired 
click paradigm. The CU condition contained more males (n= 9) than females (n = 5) 
while the NU condition contained more females (n = 12) than males (n = 4). A chi-square 
test for independence was performed to examine differences between cannabis use groups 
on sex distribution; the relationship between these variables was significant, X2 (1, N = 
30) = 4.69, p = .03. Cannabis use groups did not differ on measures of age, education, or 
weekly alcohol consumption (see Table 1). There were significant differences between 
groups on total AUDIT score. While both groups were below the clinical cut off (i.e., 8) 
for risky drinking behaviours CUs (M = 6.92, SD = 4.78) were closer to this cut off than 
NUs (M = 2.30, SD = 2.02; p = .001). There were also significant differences between 
cannabis groups on four of the drug subscales measured: tobacco (MCU = 6.00, SDCU = 
6.61; MNU = 0.31, SDNU = 0.87; p = .002), alcohol (MCU = 12.14, SDCU = 8.26; MNU = 
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6.31, SDNU = 4.06, p = .018), cannabis (MCU = 17.71, SDCU = 8.98; MNU = .75, SDNU = 
1.34; p < .001) and cocaine (MCU = 3.64, SDCU = 6.03; MNU = .19, SDNU = .75; p = .031). 
CUs were above the clinical cut off for levels of use needing intervention on the tobacco, 
alcohol, and cannabis subscales. Non-users reported no use of amphetamines and 
hallucinogens; therefore, groups were not compared (see Table 1). Participants were not 
consistent in the manner in which they reported their THC:CBD content (e.g., while some 
provided exact ratios, other suggested they bought the highest THC content available at 
the time); this variability in reporting it made it impossible to determine the actual ratio of 
THC:CBD present in the cannabis used by our participants. Thus, this data proved to be 
inconsistent and at times unquantifiable; therefore, it was not used for analysis.  
Cannabis users were using, on average, almost 5 days a week (M = 4.7, SD = 2.7) 
for a consistent period of about 4 years, on average (M = 3.7, SD = 3.03, range = 1-10 
years). Based on the age of our sample, this suggests that the average cannabis user in our 
sample began use around the age of 18 years.  
The ReSUS was administered to all cannabis users in our sample to help gain a 
better understanding of the reasons why our participants’ consumed cannabis. 
Participants total scores on the ReSUS were divided into the three subscales of the 
ReSUS (i.e., coping with distressing emotions and symptoms, social enhancement and 
intoxication, and individual enhancement; Gregg et al., 2009) with high scores on each 
subscale representing a higher risk of consumption for those reasons. A full analysis of all 
38-items was done to determine the frequency in which each motivation is reported, the 
most reported reason for cannabis use in our sample was for social enhancement and 
intoxication where “when I want to chill or relax” was the most reported reason for use 
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(57%). Other common reasons for use were “when I want to feel good, have a laugh or be 
happier”, and “when I am with friends, and we want to have a good time”, each of which 
was reported in 50% of our cannabis using sample (for a full breakdown of reasons see 
Table 2). 
2.10.1 Cannabis Users Versus Non-Users’ Analysis.  
Due to insufficient sex-specific sample sizes within our CU and NU conditions, a 
fully factorial analysis between cannabis use and sex on our ERP measures was not able 
to be completed as proposed. Please see COVID-19 limitations in appendix D  for further 
explanation as to why this analysis was not possible at this time. 
 2.10.1.1 Amplitude  
Repeated measures ANOVA revealed a main effect of stimulus type identified for 
P50 amplitude, F (1,28) = 22.23, p < .001, such that S1 amplitude was larger than S2 for 
both CUs (MS1 = 1.75 μV, SDS1 = 1.14; MS2 = .55 μV, SDS2 = .58, p = .006) and NUs (MS1 
= 1.54 μV, SDS1 = 1.75; MS2 = .64 μV, SDS2 = .76; p = .004, CI [ S1: CU: 1.09 – 2.42; 
NU: .90 – 2.18; S2: CU = .21 – .89; NU: .24 – 1.04]; Table 3). There was neither a main 
effect of group (Figure 1) or a group by stimulus type interaction (Table 4). Effect sizes 
and confidence intervals (CI [-1.09 - .67]; CI [-.43 - .60], S1 and S2 respectively) 
corroborated the between-groups findings with inconsequential effects, suggesting no 
differences between CUs and NUs as measured by Hedges’ g (gS1 = .18, gS2 = .12, 
respectively).  
Ratio and difference scores showed no main effects of cannabis use (Table 5) 
suggesting no differences between CUs and NUs on gating measures. Effect sizes and 
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confidence intervals were generated for rP50 (g= .40) and dP50 (g = .24; CI [ ratio 
scores: -.37 – 1.18; difference scores: -1.22 - .61], indicating there was only a small effect 
of cannabis group for both ratio and difference scores.  
There were no main effects or interaction effects for the N100 amplitude for the 
paired click paradigm (Table 4), and effect sizes and confidence intervals were 
inconsequential and small (respectively) suggesting no difference between groups (g = 
.02; CI [ -1.64 – 1.51]) and no interaction between groups and stimuli S1 (g = .30) or S2 (g 
= .38, CI [S1: CU = [-3.43 – (-.28)], NU = [-4.27 – (-1.32)]; S2: CU = [-3.76 – (-1.43)], 
NU = [-2.87 – (-.70)] Figure 2). Ratio and difference scores showed no statistically 
significant differences between groups (Table 5); however, effect sizes and confidence 
intervals helped better understand these potential differences. Effect sizes were medium-
to-large, suggesting the possibility of a between-groups effect, such that, CUs have larger 
ratios (M = 1.20, SD = .38) relative to NUs (M =.36, SD = .34; p = .11, g = .80; CI [ -1.88 
- .21]). Effect sizes for difference scores suggest CUs have smaller difference scores 
relative to NUs (MCU = .73, SDCU = 2.98; MNU = -1.01, SDNU = 2.63; p = .098, g = .63; CI 
[ -3.85 - .35], Figure 3). Confidence intervals for both ratio and difference scores suggest 
these findings should be interpreted with caution and further research is needed. These 
findings suggest the possibility of worse sensory gating as indexed by the N100 in the 
CU group relative to the NU group, however, indicate more research is needed to fully 
understand this relationship.  
There was no main effect of stimulus type for P200 (Table 4, Figure 2); and no 
stimulus-by-group interaction, F (1, 28) = 4.14, p = .052, Figure 4. Planned pairwise 
comparisons revealed CUs (M = .01 μV, SD = 3.32) had smaller amplitudes to S1 than 
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NUs (M = 2.93 μV, SD = 3.45; p = .03, g = .86; CI [ .37 – 5.46]). Pairwise comparisons 
revealed the between-group differences for P200 amplitudes to S2 were non-significant, 
small effect sizes and wide confidence interval ranges suggesting no difference between 
cannabis use groups on P200 amplitudes to S2 (MCU = 1.25, SDCU = 2.87; MNU = 1.19, 
SDNU = 2.23; p = .95, g = .02; CI [-1.85 – 1.97]). 
 2.10.1.2 Latency  
There were no main effects of stimulus type or cannabis group on P50 latency and 
no interaction effect (Table 4). Effect sizes and confidence intervals were generated for 
between groups effects. Broad confidence intervals and small effect sizes for S1 between 
groups suggests no differences between CUs and NUs on S1 latency (MCU = 108.85 ms, 
SDCU = 7.47; MNU = 105.88 ms, SDNU = 5.44; p = .22, g = .46; CI [-7.83 – 1.86]). 
Medium effect sizes were found for S2 suggesting CUs may have longer latencies to S2 
than NUs (MCU = 108.00 ms, SDCU = 8.81; MNU = 104.63 ms, SDNU = 4.11; p = .18, g = 
.50; CI [-1.66 – 8.41]) confidence intervals suggest more research is needed to fully 
understand this finding. 
A main effect of stimulus type was found, F (1,28) = 91.09, p < .001, for the 
N100 latency such that latencies were shorter for S1 (M = 121.67 ms, SD = 31.78) than 
S2 (M = 179.86 ms, SD = 23.39, g = 2.09). Pairwise comparisons revealed that this was 
consistent across groups ([S1]: MCU = 112.42 ms, SDCU = 28.07; MNU = 129.75 ms, SDNU 
= 33.47, p < .001; [S2]: MCU = 177.57 ms, SDCU = 27.65; MNU = 181.87 ms, SDNU = 
19.65; p < .001). There was a medium effect-size for the simple main effect of group (g = 
.55) however, confidence intervals suggest this finding needs further exploration (CI [-
5.98 – 40.62]).  The effect sizes and broad confidence intervals for the S2 group simple 
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main effect suggest, there may be no differences between groups (g = .18; CI [-13.46 – 
22.07]), despite significance test findings. 
A main effect of stimulus type was found for P200 latency F (1,28) = 39.56, p < 
.001, such that S1 (M= 167.87 ms, SD = 58.67) had shorter latencies than S2 (M = 231.47 
ms, SD = 38.63; CI [43.81 - 86.13]). There were no significant main effects of group, F 
(1,28) = 3.96, p = .057. While large effect sizes appear to suggest CUs (M = 184.93 ms, 
SD = 10.15) have shorter latencies than NUs (M = 212.56 ms, SD = 9.49, g = 2.8; CI [ -
.83 – 56.10]), confidence intervals suggest caution is needed when interpreting this 
finding. While there was no stimulus type by group interaction revealed, F (1,28) = 3.98, 
p = .056; pairwise comparisons indicate latencies were quicker for S1 in CUs (M = 109.38 
ms, SD = 57.38) relative to NUs (M = 142.14 ms, SD = 50.44, p = .022, g = .61; CI [7.55 
– 88.91]; Figure 4). Pairwise comparisons suggest no differences between CUs (M = 
227.71 ms, SD = 45.36) and NUs (M = 234.75 ms, SD = 32.81; p = .63, g = .17; CI [-
22.31 – 36.38]) on S2 latencies (see Figure 5). 
2.10.1.3 Correlations   
Spearman’s rho bivariate correlations were performed to measure the 
relationships of the MLAER components with the demographic and psychological 
variables. The N100 (S2) amplitude was negatively correlation with alcohol use (r = -.45, 
p = .01) as measured by the ASSIST, such that as alcohol use increases, N100 amplitude 
to S2 decreased (i.e., became larger). Risky alcohol use as measured by the AUDIT was 
found to correlate with P200 amplitude (S1) such that as risky drinking behaviours 
increased, P200 amplitude decreased (r = -.39, p = .04). 
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Significant correlations were found for cannabis users’ scores on the ReSUS 
individual enhancement scale and the P50 measures of inhibition, specifically P50 S1 (r = 
-.58, p = .03), rP50 (r = .54, p = .05) and dP50 (r = -.57, p = .03). This pattern suggests 
that increased use for individual enhancement is associated with decreased P50 amplitude 
for S1 and worse overall gating as indexed by decreases in dP50 and increases in rP50. 
There was also a correlation with N100 amplitude and the ReSUS subscales, specifically 
N100 S1 amplitude negatively correlated with the ReSUS coping with distressing 
emotions and symptoms subscale (r = -.56, p = .04) and the ReSUS social enhancement 
and intoxication subscale (r = -.63, p = .02). These correlations point to the fact that 
increased use of cannabis for coping or social reasons would decrease N100 amplitude 
(making it more negative).  
dN100 and N100 S1 latency also correlated with the ReSUS coping with 
distressing emotions and symptoms subscale (r = -.57, p = .032; r = .55, p = .004 
respectively) suggesting that as cannabis use for coping reasons increases, sensory gating 
as indexed by the N100 gets worse, and N100 S1 latency gets longer. 
2.10.1.4 Summary  
Overall, these analyses are underpowered (see section 2.10); while we found no 
statistically significant differences between groups and confidence intervals suggest no 
differences our effect sizes suggest possible differences between groups may exist. 
Specifically, it appears that P50-indexed gating is not impaired in cannabis users, while 
the later, early attentive phase (as indexed by the N100) may be more impacted by 
cannabis use. Latency findings suggest that P50 latencies were longer for cannabis users 
while the later processing appears to be quicker (i.e., N100 and P200) as indexed by 
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shorter latencies in CUs (vs. NUs) to S1 and S2 stimuli. All findings need to be interpreted 
with caution as our confidence intervals suggest more research is needed to fully 
understand these relationships. 
Correlational findings suggest decreases (i.e., more negative) in S2 N100 and S1 
P200 amplitudes may be related to increased alcohol use. While decreased N100 
amplitudes goes against prior findings with alcohol users (Miyazato & Ogura 1993; 
Kaseda et al., 1994; Sklar & Nixon, 2014) very little research has been done examining 
this component with this sample (alcohol users). Prior work suggests larger N100 
amplitudes may be related to situations inducing high levels of cerebral cortex activation 
such as states of anxiety or stress (Ermutlu et al., 2005; Golimbet et al., 2013; Rosbuurg 
et al., 2008; Schofield et al., 2009). With the known relationship between alcohol use and 
anxiety disorders, it may be that the correlation between N100 amplitudes and alcohol 
use are impacted by anxiety. Unfortunately, anxiety was not measured in this study and 
thus we cannot further explore this relationship. While Sklar and Nixon’s (2014) found 
increased N100 amplitudes in alcohol users, thus going against what we found, our 
findings do perfectly align with their P200 findings such that they found reduced 
amplitudes to S1 for those that received moderate doses of alcohol (BrAC = .0065%), 
suggesting that alcohol use impacts the P200 (S1) amplitude.  
Additionally, correlations revealed that an increased use for individual 
enhancement was associated with decreased S1 P50 amplitude and decreased dP50 
suggesting those who used for individual enhancement have worse gating ability and 
worse gating-in (as indexed by smaller S1 amplitudes) compared to cannabis users who 
primarily use for other reasons. Another correlation was found between reasons for use 
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and the MLAERs such that use for coping or social reasons correlated with decreases in 
N100 amplitudes increases in N100 latencies. This suggests that the reasons behind why 
someone uses cannabis are an important factor to consider when examining how sensory 
gating may be impacted as they may represent trait-level differences independent of drug 
use. 
2.10.2 Male Versus Female Analysis Covarying for Weekly Cannabis Use.  
 2.10.2.1 Amplitude  
 There was a main effect of stimulus type identified for P50 amplitude, F (1,27) = 
7.0, p = .013, such that while accounting for weekly cannabis use and sex, S1 (M = 1.64 
μV, SE = .23) amplitudes were larger than S2 (M = .60 μV, SE = .13, g = 1.11). No 
stimulus by sex interaction was identified (p = .114, Figure 6). While accounting for 
weekly cannabis use, the effect size for sex was small for S1 (g = .41) and inconsequential 
for S2 (g = .10), confidence intervals substantiate this finding CI S1(female [1.33 – 2.53], 
male [.58 – 1.96]); S2 (female [.19 - .91], male [.26 – 1.08], suggesting no difference 
between sexes for either stimulus type (Table 6). Ratio and difference scores were 
examined, no main effects of sex were found (Table 7). Effect sizes, and confidence 
intervals were generated for rP50 and dP50 separately. These were inconsequential and 
small, again suggesting that there are no differences between sexes on rP50 (g = .18; CI 
[.23 - .48) and dP50 (g = .45, CI [.59 – 1.49) measures of sensory gating. 
 There were no main or interaction effects observed for N100 amplitude to the 
paired click paradigm (Table 6). Inconsequential to small effect sizes of sex supported 
this suggesting no effect of sex on S1 (g = .10; CI [.28 – 1.53]) or S2 (g = .20; CI [.54 – 
1.87]) amplitudes (Figure 7). N100 ratio and difference scores indicated no main effect of 
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sex while accounting for weekly cannabis consumption (Table 7). In agreement with this, 
effect sizes were small and inconsequential, and confidence intervals had wide ranges, 
thus, suggesting no difference between males and females on gating ratios (g = .47; CI [-
.23 – 1.57]) or difference scores (g = .01; CI [-1.32 – 3.30]).  
Finally, the analysis of P200 amplitude showed no main or interaction effects 
while controlling for the impact of weekly cannabis use (Table 6). Effect sizes supported 
this conclusion with inconsequential between-sex effects on P200 amplitude for both S1 
(g = .17; CI [ -5.15 - .11]) and S2 (g = .19, CI [-1.28 – 2.54]; Figure 7).  
 2.10.2.2 Latency  
 There were no main or interaction effects for P50 latency while accounting for 
weekly cannabis consumption (Table 6). Confidence interval ranges and inconsequential 
effect sizes suggested there were no between sex effects for S1 or S2 amplitude (g = .036, 
CI [-10.50 -  10.61], g = .14, CI [-12.26 – 11.83] respectively). A main effect of stimulus 
type was discovered for the N100 latency analysis, F (1,27) = 38.06, p < .001. Pairwise 
comparisons revealed that this was due to smaller latencies to S1 (M = 122.93 ms, SE = 
5.82) than S2 (M = 180.06 ms, SE = 4.47, g =2.08). The results suggested no main or 
interaction effects of sex on N100 latency while accounting for weekly cannabis use. 
Effect sizes and confidence intervals support this conclusion with inconsequential to 
small effects, and broad ranges between sexes for N100 latency for both S1 (g = .38; CI [ 
-20.42 – 51.59]) and S2 (g = .14; CI [ -31.52 – 43.78]).  
 A main effect of stimulus type was found for the P200 latencies, F (1,27) = 11.11, 
p = .002; pairwise comparisons indicated this was due to shorter latencies at S1 (M = 
170.67 ms, SE = 10.42) when compared to S2 (M = 232.17 ms, SE = 7.33, g = 1.28). 
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There was no interaction effect found between sex and stimulus type for P200 latency (p 
= .20). In addition, effect sizes for sex for each stimulus type were small and confidence 
interval ranges were very large, suggesting no impact of sex on P200 latency for either S1 
(g = .41; CI [-30.79 – 91.78]) or S2 (g = .23; CI [-70.01 – 55.71]).   
 2.10.2.3 Summary  
We found a main effect of stimulus type for the P50 amplitude in addition to main 
effects of stimulus type for latency for the N100 and P200 ERPs; however, there were no 
main or interactive effects of sex. Overall, these findings are underpowered (see section 
2.9); however, our analysis in conjunction with effect sizes and confidence intervals 
suggest no evidence of sex-based differences in amplitude of the MLAERS or latency of 
these components.  
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Chapter 3: Go/NoGo Paradigm   
Participant information, study procedure, questionnaires, and EEG recording and 
computation, were all identical to that previously described; please see chapter 2 section 
2.1 -2.4 for full information.  
3.1 Test Battery  
The Go/NoGo paradigm is a well-established visual task (Maij et al., 2017; 
Salisbury et al., 2004) that required participants to withhold a behavioural response when 
presented with an infrequent ‘NoGo’ stimulus (P=0.25) randomly embedded among 
frequent ‘Go’ stimuli (P=0.75). Stimuli were white numbers between 1-9 presented on a 
black computer screen; participants were instructed to press the mouse key (i.e., ‘go’) for 
every non-repeated number, but to withhold their response (i.e., ‘no go’) when repeated 
numbers were shown (see Figure 8). Stimuli were presented in four blocks of 150 trials 
each (i.e., 600 total trials) in a pseudo-randomized order, such that no number was 
presented more than two times in a row (Maij et al., 2017). Each number was presented 
for 700 ms, with an interstimulus interval of 300 ms.  
3.2 ERP analysis  
The Go/NoGo paradigm allowed us to measure several components of interest 
(i.e., the P100 and P300 for both the Go and NoGo stimuli), specifically the inhibitory 
NoGo P300. To be consistent with previous research (Spronk et al., 2016), we applied 
filters from 0.10-30 Hz and a notch filter at 60 Hz. Data was then segmented into Go and 
NoGo trials separately including 100ms before and 700ms after each stimulus. Electrical 
epochs (800 ms period, commencing 100 ms pre-stimulus) were corrected for eye 
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movement (residual movement and blinks) using the Gratton and Coles algorithm 
(Gratton, Coles, & Donchin, 1983). The data was then baseline corrected between -100 – 
0 ms and put through an artifact rejection process whereby data with a 20µV/ms or 
greater voltage step or containing electrical activity exceeding ±75 µV were excluded 
from the analysis. The remaining epochs were then averaged, with the resulting 
waveform used to identify the peaks. 
Peak identification took place at the respective sties of maximal amplitude of each 
ERP of interest. The site of maximal amplitude varied for each component, with the Go 
components having a more posterior distribution (i.e., Go P300 – Pz) whereas the NoGo 
components have a more centro-parietal topography (i.e., P300 – Cz; Salisbury et al., 
2004). P100 amplitudes were also of interest with a site of maximal amplitude occurring 
at Oz for both the Go and NoGo conditions. Peak amplitudes were quantified as the most 
positive or negative deflection within the identified peak detection windows. Peak 
detection windows were determined based on grand averaged waveforms: (P100 for both 
Go and NoGo: (80 – 150 ms); Go P300: (375 – 500 ms); NoGo P300: (200 – 350 ms)). 
Participant data was averaged in preparation for peak identification; a semi-automatic 
process involving verification by the first author (AMF) was used to identify peak 
amplitude separately for each participant. Latency (time to reach peak amplitude from 
stimulus onset) was derived for each component from the averaged waveform of the Go 
and No/Go trials separately for each participant.  
3.3 Behavioural analysis 
The average number of misses (i.e., missing a response to a Go trial), and false 
alarms (i.e., incorrect response during a NoGo trial) for the Go/NoGo task were 
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determined by generating averages across all four blocks of the task. Proportional 
averages for reaction time across all four blocks were also generated for false alarms and 
correct responses. In addition, proportional percent correct and false alarms was created . 
Two one-way ANOVAs were used to determine group (CU and NU) and sex (Male and 
Female) differences on behavioural performance measures (i.e., percent correct, false 
alarms, proportional reaction time, misses).  
3.4 Statistical analysis  
 A mixed ANOVA was conducted using SPSS 24 (SPSS Inc., Chicago, IL) 
separately for each ERP of interest within this paradigm. Each analysis is fully described 
below.  
Go analyses included the analysis of the P100 and P300 waveforms. All ERPs 
were analyzed using separate mixed ANOVAs that included the following variables: one 
between groups measure (2 levels: CU and NU) and two within groups measures: Region 
(2 levels: parietal and occipital) and Scalp site (3 levels: left, midline, and right). A 
separate set of mixed ANOVA analyses was conducted for each ERP component of 
interest using sex as the between-groups measure and adding in the covariate of weekly 
cannabis use. Non-significant F-test parameters are reported in Table 9. These values are 
only reported in text when significant (i.e., p < .05) or at the non-significant trend level 
(i.e., p = .07 - .05).  
NoGo analysis included a similar approach for the P100 and P300 ERP 
components with separate mixed ANOVAs being performed for each. For the P100 the 
variables of interest were one between groups measure (2 levels: CU and NU) and two 
within groups measures: Region (2 levels: parietal and occipital); and Scalp site (3 levels: 
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left, midline, right). The P300 has a site of maximal amplitude at Cz; therefore, the 
analysis for the P300 focused on more central electrodes using the same between groups 
measure (2 levels: CU and NU) and modifying the within-groups measure of region to 
include frontal and central regions (2 levels: frontal and central). Site remained the same 
with three levels (left, midline, right). As was done with the Go analysis, a separate 
mixed ANOVA was performed for each ERP with sex as the between-groups factor and 
adding the covariate of weekly cannabis use, with non-significant F-test parameters 
reported in Table 9. These values are only reported in text when significant (i.e., p < .05) 
or at the non-significant trend level (i.e., p = .07 - .05). Amplitudes for the NoGo stimuli 
are the focus of our results, as they assess inhibitory processing.  
Latency was calculated as the time to reach peak Go/NoGo amplitude from 
stimulus onset. Latencies were calculated for each of the Go and NoGo ERPs of interest 
separately. Univariate ANOVAs were computed separately for the latency corresponding 
to each of the ERPs of interest, with a dependent factor of latency and fixed factor of 
cannabis use (CU and NU). In addition to this, separate univariate ANOVAs were 
performed for the latency of each ERP of interest to measure sex as a fixed factor with 
latency as the dependent variable and weekly cannabis use as a covariate. As with 
amplitudes, non-significant F-test parameters are reported in Table 9. These values are 
only reported in text when significant (i.e., p < .05) or at the non-significant trend level 
(i.e., p = .07 - .05). 
Bivariate correlational analyses were conducted in a similar manner to what was 
previously described (see Chapter 2, section 2.8 for full details). As was done with the 
MLAERs, a priori planned comparisons were performed for any cannabis use, sex and 
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neurophysiological outcomes (i.e., amplitude and latency). Additionally, the same 
process was followed as to what is described in Chapter 2 regarding the probing of 
interactions and the calculation of effect sizes (please see Chapter 2, section 2.8 for full 
details). 
3.5 Go/NoGo Power Analysis  
Power analyses were conducted separately for each component (P100 and P300) 
to determine observed power (post-hoc analysis; see section 3.5 for outcome of the power 
analysis), the statistical test used was an independent samples t-test as this would allow 
sufficient power to detect differences between groups (i.e., cannabis conditions and sex). 
Two tailed tests with the following effect sizes (P300: Go - small (d = .07), NoGo- small 
(d = .25) P100: Go – medium (d = .68), NoGo – small (d = .18) were used along with the 
appropriate group size (i.e., CU vs. NU analysis: n = 14, n = 16; Sex based analysis: n = 
13, n = 17).  A priori analyses were also conducted using the independent samples t-test 
as the statistical test, all while maintaining 80% power. Effect sizes for the P300 were 
based off (Salisbury et al., 2004). Due to the novelty surrounding the P100 ERP in our 
sample (cannabis users) we were unable to conduct an a priori power analysis. 
The observed power for between-group (CU vs NU) differences (ANOVA) for 
the P300 in the Go and NoGo condition were 10% and 5% respectively. This suggested 
we would need an unrealistic sample size of 478 to expect to see between-group 
differences for the P300 Go and 12,562 to see between-group differences for the P300 
NoGo. Given these are substantially larger than normal sample sizes for ERP studies this 
suggests there are truly no differences between cannabis groups in P300. With the 
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novelty in the area of the P100 in this sample (cannabis users) no a priori power analyses 
were able to be obtained for this ERP.  
3.6 Results  
Participants were the same as those described in Chapter 2, thus demographic 
information for this sample can be found in Chapter 2, section 2.10. 
3.6.1 Cannabis users vs non-users’ analysis.  
Due to insufficient sex-specific sample sizes within our CU and NU conditions, a 
fully factorial analysis between cannabis use and sex was not able to be completed as 
proposed for the ERP components. Please see COVID-19 limitations in the discussion for 
further explanation as to why this analysis was not possible at this time.  
One CU male participant had to be excluded from this analysis due to missing 
data (e.g., no trigger information or behavioural data was captured during this task). The 
final sample size for the Go/NoGo paradigm was thus n = 29.  
3.6.1.1 Amplitude Go  
 There was a main effect of region, of moderate effect size, for P100 amplitude in 
the Go condition, F (1,27) = 14.05, p = .001, with larger amplitudes in the occipital (M = 
3.47 μV, SD = 2.90) compared to parietal (M = 1.95 μV, SD = 2.91, g = .52; CI [.71 – 
2.41]) region. The ANOVA revealed there were no region by group (p = .30) or region by 
site by group interactions (p = .61). Effect sizes arising from for a priori between-group 
comparisons at the region of maximal amplitude (occipital). This suggested medium 
sized differences between cannabis groups such that CUs (M = 4.32 μV, SD = 3.40) had 
larger P100 amplitudes than NUs (M = 2.78 μV, SD = 2.28, p = .14, g = .50, CI [-2.54 – 
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1.20], Figure 9). Finally, the P300 Go amplitude was assessed for group differences. 
There were no main effects or interaction effects. Effect sizes indicated medium effects at 
the region of maximal amplitude (parietal) suggesting CUs (M = 4.82 μV, SD = 2.29) had 
larger P300 Go amplitudes than NUs (M = 3.55 μV, SD = 2.70; p = .16, g = .50) however, 
confidence intervals suggest more research is needed to understand this relationship (CI 
[-3.08 - .54]). 
3.6.1.2 Amplitude NoGo  
A main effect of region was found for the P100 NoGo amplitude F (1,27) = 21.14, 
p < .001, due to larger amplitudes in the occipital (M = 3.86 μV, SD = 2.85) compared to 
parietal (M = 2.11 μV, SD = 2.97, g = .60; CI[.99 – 2.59]) regions. There was no other 
main or interaction effects. While this suggested no impact of group on the P100 NoGo 
amplitude, effect sizes suggested otherwise and indicated that at the region of maximal 
amplitude (occipital) there was a medium effect size of group, with CUs (M = 4.66 μV, 
SD = 2.97) having larger amplitudes than NUs (M = 3.21 μV, SD = 2.66, p = .15, g = .52, 
CI[ -3.45 - .54], Figure 10), although confidence intervals corroborate findings of no 
differences between groups.  
 Finally, the NoGo P300 was assessed, and a main effect of region was found, F 
(1,27) = 38.98, p < .001. Pairwise comparisons revealed these differences were due to 
significantly larger P300 amplitudes at the central (M = 7.79 μV, SD = 4.34) compared to 
frontal (M = 4.92 μV, SD = 3.36, g = .74; CI [2.02 – 3.10]) region. There were no other 
main or interaction effects, suggesting no differences between CUs and NUs. Effect sizes 
and confidence intervals substantiate this finding as the effect between CUs (M = 7.81 
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μV, SD = 2.69) and NUs (M = 7.78 μV, SD = 5.26, p = .98; CI [-3.19 – 3.11]) at the 
central region was inconsequential (g = .01). 
 3.6.1.3 Latency  
 A one-way ANOVA was conducted to measure the latency of each ERP of 
interest at the site of maximal amplitude. We found no between-group differences on 
measures of latency for any of our ERPs of interest. In addition, all between-group effect 
sizes were inconsequential and small suggesting no impact of group on latencies (Table 
9).  
3.6.1.4 Correlations  
 Spearman’s Rho bivariate correlations were performed to assess our behavioural 
measures of Go/NoGo performance on our demographic variables. We found that 
tobacco use as measured by the WHO ASSIST was negatively correlated with correct 
reaction time (r = -.37, p = .046) indicating that as self-reported tobacco use scores 
increased, response time for correct responses decreased. We also found correlations with 
total number of false alarms and total AUDIT scores (r = -.55, p = .002) such that as 
AUDIT scores increased, number of false alarms decreased. In addition, false alarms 
were found to correlate negatively with self-disclosed weekly alcohol consumption (r = -
.43, p = .019) indicating as weekly drinking increased false alarms decreased.  
 Behavioural measures were found to correlate with our ERPs of interest in the 
following ways. Overall, P300 Go latency correlated negatively with total false alarms (r 
= -.62, p < .001) indicating more false alarms were made when P300 latency was shorter. 
With regard to the NoGo correlational findings, NoGo P300 amplitude was found to 
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correlate with several behavioural factors, specifically, the percentage of correct 
responses made by participants (r = .48, p = .009), the total false alarms made (r = -.41, p 
= .029), reaction time for the false alarms (r = -.43, p = .019), and the number of misses 
made by participants (r = -.48, p =.009). This suggests that the larger the amplitude, the 
more correct responses were being made while the false alarms (reaction time and 
behavioural response) and misses made decreased as amplitude increased (or vise-versa).  
 To better understand the nature of these correlations, the sample was divided 
between CUs and NUs to determine if one group was driving these correlations. The 
correlation between false alarm reaction time and the P300 NoGo amplitude was only 
present in the CUs (r = -.52, p = .039). In addition, a new correlation was found for the 
CUs between total number of false alarms made and P300 Go amplitude (r = -.62, p = 
.011) suggesting that P300 amplitude for both conditions of the Go/NoGo task is 
decreased when false alarms are increased in quantity or reaction time. Interestingly, 
there were no correlations with false alarms (reaction time or quantity) within the NUs. 
The correlations between percent of correct responses (r = .56, p = .048) and number of 
misses made (r = -.56, p = .048) with NoGo P300 amplitude appear to be driven by NUs. 
This suggests P300 amplitude in CUs is not associated with the number of correct 
responses made; however, it is associated with the number of false alarms made. There 
were no other significant correlations to report.  
3.6.1.5 Behavioural  
Analysis of behavioural data revealed that cannabis users and non-users did not 
differ on any of the behavioural measures (i.e., percentage of correct responses, reaction 
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time for correct responses, false alarms, reaction time on false alarms, and misses; see 
Table 8). 
 3.6.1.6 Summary  
 Overall, these findings are underpowered (see section 3.5); while our statistical 
findings and confidence intervals suggest no differences between groups, our 
supplemental effect size analysis suggests differences between groups may exist. 
Specifically, while confidence intervals suggested no real differences exist, effect sizes 
suggested CUs may have enhanced P100 and P300 Go amplitudes compared to NUs. 
Overall, this signifies that more research needs to be done to clarify these potential 
differences. 
3.6.2 Male versus Female Analysis Covarying for Weekly Cannabis Use.  
 3.6.2.1 Amplitude Go 
 Repeated measures ANOVAs were run to measure sex differences on our ERPs of 
interest while controlling for the impact of weekly cannabis use. For the Go P100, a main 
effect of region was found, F (1, 26) = 16.59, p < .001. Pairwise comparisons revealed 
this was due to larger amplitudes in the occipital (M= 3.62 μV, SE = .51) compared to 
parietal (M = 1.95 μV, SE = .45; CI[.84 – 2.50]) region. No interaction effect was found 
between region and sex, F (1,26) = 4.10, p = .053. Pairwise comparisons were done and 
revealed males had significantly larger P100 amplitudes in the occipital (M = 4.51 μV, SE 
= .81) region when compared to the parietal region (M = 1.97 μV, SE = .72, p = .001). 
The amplitudes in females were not significantly different across region (p = .16). 
Further pairwise comparisons revealed that there were no differences between male and 
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female P100 amplitudes at either region ([parietal] p = .98; [occipital] p = .12). Effect 
sizes were generated to determine the effect between groups at the site of maximal 
amplitude (Oz): a medium/large effect was found in support of our main finding 
indicating that males have larger amplitudes than females (g = .74; CI[-4.04 - .47], Figure 
11). There were no other main effects or interaction effects found for the P100 Go. 
 A main effect of region was also found for the P300 Go ERP, F (1, 27) = 33.08, p 
< .001, reflecting larger P300 Go amplitudes in the parietal (M = 4.18 μV, SE = .44) 
compared to occipital region (M = 1.32 μV, SE = .47; CI[-1.0 - .78]). There were no other 
main or interaction effects found. Effect sizes were calculated between groups, at the site 
of maximal amplitude (Pz); these also suggested an inconsequential effect of sex on P300 
Go amplitude (g = .019). 
3.6.2.2 Amplitude NoGo 
Similar to the P100 Go, a main effect of region was found for the P100 NoGo, F 
(1,26) = 19.80, p < .001, reflecting larger amplitudes in the occipital (M = 3.90 μV, SE = 
.51) compared to parietal regions (M = 2.05 μV, SE = .47; CI[1.85 – 3.82]). There were 
no other significant main, or interaction effects found. Effect sizes at the site of maximal 
amplitude (Oz) were generated to determine if there were any effects between groups. 
This analysis revealed only a small effect of sex: M = 4.02 μV, SE = .70 [males] vs. M = 
3.77 μV, SE = .58 [females]; g = .21; CI [-2.76 – 3.17]. A main effect of region was also 
found for the P300 NoGo, F (1,26) = 22.53, p < .001, such that amplitudes in the central 
(M = 7.71 μV, SE = .79) region were larger than amplitudes in the frontal (M = 4.87 μV, 
SE = .63, CI [1.85 – 3.82]) region. No other main or interaction effects were found. Effect 
sizes of sex for the site of maximal amplitude (Cz) suggest only a small effect of sex: M = 
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8.66 μV, SE = 1.57 [males] vs. M = 10.19 μV, SE = 1.30 [females]; g = .23, CI [-2.79 – 
5.87]. 
3.6.2.3 Latency 
There was no main effect of biological sex found suggesting no difference 
between groups on P100 or P300 latency for the Go stimuli while controlling for weekly 
cannabis use (p = .27, p = .71, respectively). Effect sizes for sex on the latency of each 
were calculated and suggest only inconsequential to small magnitude differences between 
males and females on the latency of P100 (g = .38) and P300 (g = .15). 
There was no main effect of sex on latency measures for the NoGo P100 or P300 
(p = .43, p = .38, respectively). Effect sizes suggest an inconsequential difference 
between males and females for the P100 (g = .004); however, the effect size for the P300 
latency suggests a medium effect such that females (M = 393.45 ms, SE = 14.06) have 
shorter latencies than males (M = 425.45 ms, SE = 16.95, g = .53; CI [-78.88 – 14.87]). 
3.6.2.4 Behavioural 
The data was divided by sex and behavioural measures were assessed for group 
differences. No sex differences were found on any of the behavioural measures of 
interest. 
3.6.2.5  Summary  
We found main effects of region were shown for all ERPs of interest such that 
there were larger amplitudes in the occipital (vs. parietal region) for the P100 Go and 
NoGo stimuli. Additionally, the Go P300 had a main effect of region with largest 
amplitudes in the parietal (vs. occipital) region while NoGo P300 showed maximal 
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amplitudes at central sites (vs. frontal). Overall, our findings suggest no differences 
between males and females Go/NoGo measures of P300 or NoGo P100 processing.  
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Chapter 4: Discussion 
4.1 Primary outcomes  
4.1.1 Amplitude and Latency 
 The goal of the study was measuring the separate and combined effects of 
cannabis use and biological sex on inhibitory functioning and sensory gating as measured 
by the MLAER (i.e., P50, N100, P200) and VEP (i.e., P100, P300) components. Based 
on prior research we anticipated that cannabis users would have reductions in amplitude 
to all components and that females would present with larger P300 amplitudes than 
males. No sex-specific hypotheses were generated for the MLAER and P100 – VEP 
components due to the novelty of this area. This study originally intended on measuring 
the interactive effect of biological sex and cannabis use; however, due to unforeseen 
circumstances (i.e., pandemic-related interruption), the sample size to accurately measure 
this question was not obtained. [Please see appendix D for a description of the limitations 
of this study due to the COVID-19 pandemic].  
A stimulus main effect, consistent with prior literature for the P50 (Turetsky et al., 
2007), was found suggesting reductions in S2 amplitudes (vs. S1). Contrary to our first 
hypothesis, we found that there were no difference between CUs and NUs on P50, N100 
and P200 amplitudes. In addition to this, we found no significant differences between the 
three MLAER components between sexes suggesting no difference between males and 
females for P50 or N100 in our study. 
The lack of P50-indexed differences between CUs and NUs on measures of 
sensory gating deviates from prior work done on cannabis users (Edwards et al., 2009; 
Patrick et al., 1999; Patrick and Struve 2000; Rentzsch et al., 2007); however, it is in line 
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with recent work found by our lab (Francis et al., 2021). The difference between past 
work (Edwards et al., 2009; Patrick et al., 1999; Patrick and Struve 2000; Rentzsch et al., 
2007) may come down to the amount of cannabis consumed by our sample. While these 
prior studies report on average 9 years of heavy consistent cannabis use (beginning 
around age 15 and daily or more (upwards of 23 joints per week; Patrick & Struve, 2000), 
our sample had only been using cannabis consistently for roughly 3 years, with most 
using only 4 times a week. These discrepancies in our findings may, therefore, be more 
representative of a moderate using group with a relatively recent onset of use as opposed 
to a group of chronic and heavy cannabis users. This interpretation is supported by the 
finding that when cannabis-using participants were stratified into long and short-term 
users, sensory gating deficits were only reported only in long-term users but not short-
term users (Broyd et al., 2013). Furthermore, it has been shown that cognitive changes 
are only present with high levels of circulating THC (Hunault et al., 2009) which often 
can be reversed with periods of abstinence (Rabin et al., 2017; Schuster et al., 2018). 
While our sample was not abstinent for longer than 24 hours, it is possible that with their 
lower overall cannabis use (relative to prior samples), their cognitive functioning was not 
impacted as is seen with heavy users. These findings are consistent with recent reviews 
looking at longitudinal data and neuropsychological outcomes in cannabis users, where it 
was found that only heavy consistent cannabis users presented with neurological deficits 
(Gonzalez et al., 2017; Power et al., 2020). 
This literature helps quantify and understand our lack of significant findings 
within the Go/NoGo paradigm as well. Consistent with prior research (Salisbury et al., 
2004) we found main effects of amplitude for both Go and NoGo stimuli such that the 
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intended site of maximal amplitude (i.e., P300 (Go: Pz, NoGo: Cz); P100 (Go and NoGo: 
Oz)) had significantly larger amplitudes compared to all other sites measured for each 
stimuli (i.e., Go and NoGo). No main effects of cannabis group were found. Several other 
studies (Ilan et al., 2005; Theunissen et al., 2012) have reported deficits in Go and NoGo 
processing with acute use in heavy and occasional cannabis users. In addition, deficits 
have been shown in those with chronic use and a diagnosis of CUD (Maij et al., 2017) 
however, our study found no evidence of between group differences.  Consistent across 
these studies, however, is the fact that cannabis use was higher in years of use and joints 
per week/month than our CU condition where users were using approximately 4-5 times 
per week. This suggests that differences between our sample and past findings on 
Go/NoGo performance may be reflective of our more consistent moderate using sample. 
Behavioural measures on the Go/NoGo paradigm further support that there are no 
differences between groups on behavioural measures as well. Effect sizes suggest CUs 
may have enhanced P100 amplitudes. Given that no between-group differences were 
observed on behavioural measures, this enhancement in primary visual cortex activity 
may reflect the need for CUs to direct more cognitive resources towards the processing of 
the visual stimuli when compared to controls to achieve equivalent performance. While 
measured through different experimental designs, previous work (Hatchard et al., 2020; 
Nusbaum et al., 2017) has suggested that cannabis users have functional connectivity 
differences (e.g., CUs [vs. NUs] had decreased connectivity between the left superior 
temporal gyrus and the anterior cingulate cortex, and left orbitofrontal gyrus) even when 
behavioural measures show no group differences. Nusbaum et al. (2017) found that while 
their cannabis-using participants behaviourally performed at the same level as controls, 
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their cannabis users did not rely as heavily on typical processing modalities (top-down) 
suggesting additional neural networks are recruited to perform everyday tasks at the same 
level as non-users. Hatchard et al. (2020) found evidence of this through the use of 
functional magnetic resonance imaging where they found cannabis users relied on 
unconventional neural networks in addition to heightened processing in typically used 
networks to complete an attention task at the same level as controls. While we do not 
have imaging data to support the recruitment of additional brain networks or 
overactivation of standard networks, these findings do help explain what may be leading 
to enhanced amplitudes but equal behavioural performance in our cannabis users (vs 
controls). 
Another possible explanation for the lack of behavioural differences and the 
enhanced P100 and P300 – Go amplitudes may come from the potential relationship 
between alcohol and these modalities. Prior work has shown that when measuring 
inhibitory functioning through the Go/NoGo paradigm in alcohol dependent users, these 
users behaviourally perform at the same level as controls, however, do not rely on 
conventional neural networks to process the stimuli (Czapla et al., 2017; Stein et al., 
2020). Our CU group was also the group with the heaviest alcohol consumption and 
while their alcohol consumption was not deemed risky (as measured by the AUDIT) they 
did reach the intervention level on the ASSIST, suggesting they had significantly higher 
alcohol intake than our controls did. In addition to this our correlational findings suggest 
a relationship with alcohol use is present in our sample. Thus, the enhanced amplitudes 
found in our CUs could be due to the impact of alcohol instead of the impact of cannabis. 
It is also possible that where our CU participants are polydrug users, there is an 
 71 
interaction between cannabis use and alcohol use that is then influencing our findings. 
Without being able to parse apart this relationship and control for alcohol use we are 
unable to fully explore this potential interaction.  
 To date, only one other study has measured P100 in cannabis users. This study 
found enhanced P100 amplitudes when THC was given to heavy users but reduced P100 
when THC was given to occasional users (Theunissen et al., 2012). It is hard to compare 
the findings from this study to ours as we did not administer THC at the time of testing, 
and in fact, we had users abstain from use prior to testing. In addition, Theunnissen et al. 
(2012) found that the enhanced P100 amplitudes in heavy users were not statistically 
different from the placebo control suggesting no differences between their groups similar 
to our conclusions regarding lack of group differences on P100 in the context of the 
Go/NoGo paradigm. To our knowledge, ours is the first study to examine the P100 VEP 
in cannabis users using the Go/NoGo paradigm.  
While the P50 and NoGo P300 inform our understanding of inhibitory network 
function, there are other components that have been shown to index sensory gating 
through other neural networks. While no differences were present in the P50 gating, there 
were medium-to-large effect sizes shown for between-cannabis group differences on 
N100 gating ratio and difference scores, suggesting CUs may be impaired on these 
measures of sensory gating. These findings are in line with a previous report by our lab 
Francis et al. (2021) that suggests this may be a characteristic of cognitive deficits caused 
by moderate cannabis use. This suggests that sustained moderate cannabis use may have 
a greater impact on the later attention triggering aspects of the stimulus filtering process 
as opposed to impacting the earlier sensory inhibition process (P50) as is seen in chronic 
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users (Edwards et al., 2009; Patrick et al., 1999; Patrick and Struve 2000; Rentzsch et al., 
2007).  
Interestingly, no sex-based findings for sensory gating measures were observed, 
suggesting males and females in our sample did not differ on MLAER components. This 
is partially in line with what was found by Fuerst, Gallinat, and Boutros (2007) 
suggesting that sex had no impact on S2 components or gating ratios and that males had 
higher amplitudes for all components elicited by S1 and better (larger) difference scores. 
Our small effect sizes support the lack of statistical differences observed on these 
measures between males and females; however, given the limitations of our sample size, 
additional sex-based analyses would need to be completed in larger samples to fully 
understand the depth of this relationship and to better understand the discrepancies 
between our study and that of Fuerst et al. (2007).  
While the P200 MLAER component showed no impact of sex, there was some 
indication (medium effect size) that CUs may have reduced amplitudes to the S1 
compared to NUs. This implies that CUs may have difficulty gating-in stimuli suggesting 
they may have difficulty inhibiting a response to S1. These results as well as our findings 
surrounding the deficits in P200 amplitude are consistent with findings in those with 
schizophrenia, that suggests those with schizophrenia have difficulty with the later stages 
of sensory processing (N100, P200) which has been speculated to be a problem with the 
central nervous system’s ability to process and act on relevant information (gating-in; 
Boutros et al., 2004). It is therefore possible that CUs have similar sensory gating deficits 
that may be arising from the same pathways. While the effect size analysis suggested 
differences, our null statistical findings and confidence intervals suggest these findings 
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need to be interpreted with caution. Further exploration of these findings is necessary to 
properly understand if any differences are present. 
Our sex-based findings need to be interpreted with caution as we had significant 
sex imbalances in our CU and NU conditions, thus this imbalance may be skewing the 
findings. No other study has done a sex-based analysis with these ERPs of interest and 
thus we have very little to compare our findings to. A recent systematic review (Melynyte 
et al., 2018) suggests sex-based hormones are important to consider within P300 research, 
as hormone levels may mask any true sex-effects present between groups. While 
Melynyte et al. (2018) focused on the auditory P300 and we focused on the visual P300, 
if circulating hormone levels are influencing the auditory P300 it is possible they are also 
influencing the visual component. It is also possible that these circulating hormone levels 
are influencing the earlier components. For our study every attempt was made to ensure 
we had equal numbers of females in both their menstrual phase and mid-luteal phase to 
ensure any potential impact of hormones would be cancelled out, however, it is possible 
that there were natural fluctuations within our participants and within our male 
participants that we did not account for and that may be influencing our findings. Without 
a full saliva analysis of the hormone levels circulating in our participants at the time of 
testing we are unable to explore this possible interaction further. 
Latency findings suggest that CUs and NUs were faster at responding to the S1 
than S2 in both the N100 and P200 conditions; additionally, there was a marginal 
interaction where cannabis users had quicker P200 S1 latencies when compared to NUs. 
Given that CUs had reduced P200 amplitudes it is not surprising that they were faster to 
reach peak amplitudes when compared to NUs, which may suggest a potential speed-
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accuracy trade-off. Prior work has suggested that speed is usually prioritized over 
accuracy (Van Veen, Krug, and Carter, 2008), therefore, it may suggest that CUs are 
more focussed on responding to the stimuli instead of fully processing it. This finding 
may suggest that the later neural networks (N100, P200) are impacted by regular 
cannabis use even when it begins later in life while the earlier pre-processing networks 
(P50) may be fully developed and therefore spared, with later initiation of cannabis use. 
Our NoGo findings help support the speed-accuracy trade-off hypothesis such that 
latency negatively correlated with false alarms and misses made, suggesting that quicker 
responses led to more false alarms and missed targets (i.e., worse accuracy). Follow-up 
correlations showed that our cannabis users appeared to be more heavily impacted by this 
speed-accuracy trade-off in terms of false alarms, suggesting once again that they may be 
prioritizing fast responses at the cost of fully processing (accuracy). 
In addition to the moderate use shown in our sample relative to other cannabis 
studies, our sample also showed a later average age of initiation of steady consistent 
cannabis use compared to samples in other studies (Broyd et al., 2013; Rentzsch et al., 
2007, 2017). Based on brain development trajectories, our sample may be avoiding 
damage to neural networks during a critical developmental window by commencing 
cannabis use later in life. Longitudinal data has shown that subcortical structures and grey 
matter mature and change at different rates across adolescence depending on sex (Herting 
et al., 2019; Lenroot et al., 2007). These developmental processes have been documented 
to take place between the ages of 8-22, suggesting significant overlap with the typical 
onset of cannabis use described in the other studies at around 14 years of age (Broyd et 
al., 2013; Rentzsch et al., 2007, 2017). This, therefore, suggests that our sample should 
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have more developed neurological pathways by the time their cannabis use began, 
therefore decreasing the neurotoxic effect cannabis may have on users. This study 
provides evidence for how neurological functioning may be spared with later onset and 
moderate use of cannabis. 
Our correlational findings suggest that the later MLAER components (N100, 
P200) may be heavily impacted by alcohol use suggesting the more our participants 
consumed alcohol, the more impacted their MLAER amplitudes would be. Alcohol use 
was also found to correlate with false alarms on the Go/NoGo paradigm suggesting 
consuming more alcohol was associated with better behavioural performance (fewer false 
alarms). Prior research (Sklar & Nixon, 2014) has shown that sensory gating, specifically 
the N100 is impacted by moderate alcohol use. Given our sample ranked close to the 
intervention level (i.e., CU ranked 6.9, intervention level is 7) for alcohol use, the deficits 
in later sensory processing (i.e., N100, P200) may be related to alcohol use as opposed to 
cannabis use. In addition to this, motivations for cannabis use appear to impact the 
MLAER amplitudes, such that increased use for coping reasons was related to P50 
amplitude reductions, while increased use for social and coping reasons were negatively 
correlated with N100 amplitudes (making N100 more negative). DN100 and N100 
latency were also found to correlate with the ReSUS coping subscale such that as use for 
coping reasons increased difference scores decreased and latency increased for the N100. 
This supports our findings as our sample primarily reported use for social reasons, and 
showed shorter N100 latencies, suggesting that use for coping but not social use would 
impact latency. While this helps clarify our N100 latency finding, it is contrary to our 
findings for the dN100, whereby CUs showed smaller difference scores when using for 
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coping reasons. This may suggest that reasons for use do not heavily impact dN100 or 
that our sample is too underpowered to examine an impact.  
4.2 Study strengths 
 There are some strengths to the current study that should be noted. First, our study 
is the first study to examine the P100 VEP in otherwise healthy cannabis users in the 
absence of acute administration of cannabis. This alone aids in furthering our 
understanding of how the primary visual cortex is impacted by moderate cannabis use. 
Second, our study adds to the very limited knowledge surrounding the N100/P200 
complex in cannabis users with only one previously published study to date in this area. 
Finally, we were able to replicate sensory gating effects on the paired click paradigm 
even when including female participants and showed stimulus by cannabis group 
interactions on the P200 (amplitude and latency) that were not attributed to sex.  
4.3 Study Limitations  
 While we do believe this study adds to our current understanding of the literature 
surrounding MLAER and VEP components in males and females and cannabis users and 
non-users, the study has several important limitations reducing the confidence in our 
findings. First, our sample size was reduced compared to what was needed according to 
our a priori power analysis, therefore leaving the study potentially underpowered to find 
statistical differences. In addition, with the significant unequal sex distributions across 
cannabis use conditions, we did not have large enough sample sizes to conduct the full 
omnibus cannabis use by biological sex factorial analysis we had originally intended. 
Finally, we were unable to run an analysis with THC content of our participant’s 
preferred strain of cannabis due to inconsistent reporting by our participants. 
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Unfortunately, the THC:CBD content was not accurately disclosed by more than half of 
our sample, therefore, rendering this variable unusable.   
4.4 Future Directions  
 Due to the explained interruptions due to the COVID-19 pandemic, this study will 
continue to collect data to be able to perform the sex by cannabis group analysis that was 
originally proposed. Future work should also focus on examining the neurological 
correlates behind the P100 in the NoGo paradigm and why males showed marginally 
enhanced amplitudes relative to females. This work provided insight into how males and 
females may (or may not) differ on measures of inhibitory functioning as indexed through 
ERPs; however, continued work to investigate this is needed to fully address the question 
of whether biological sex impacts inhibitory functioning. Finally, more work should be 
done to examine how these markers of inhibition may differ based on what age cannabis 
users initiate heavy consistent cannabis use. The focus of the literature right now is on 
understanding early use as this typically intersects with brain development; however, it is 
also important to know how the brain may or may not be implicated if users wait until 
emerging adulthood to use cannabis regularly. This would be beneficial for cannabis 
campaigns aimed at younger populations to show that later use may not cause as many 
detrimental neurological deficits that early consistent use can.  
4.5 Conclusions and Implications  
While this study was not able to be completed as intended and largely indicated 
that our ERP and behavioral results did not differ based on biological sex or cannabis use, 
we were able to replicate main effects of stimulus type (i.e., suppression of S2 across for 
the P50) and regional differences (VEP) while showing no differences between groups 
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(CU vs. NU and Male vs. Female). Effect sizes and power analyses suggest we were 
underpowered to detect such effects if they did exist. Our effect sizes suggest more work 
needs to be done to better understand how users and non-users differ on early sensory 
gating and the later attention filtering and allocation mechanisms. Our sample began 
consistent use later than the samples in many other studies that have reported early 
preattentional deficits on sensory gating (Edwards et al., 2009; Patrick et al., 1999; 
Patrick and Struve 2000; Rentzsch et al., 2007) suggesting the moderate and later age of 
initiation relative to other samples may be driving these findings. Finally, our study 
suggests there is no difference between males and females on measures of sensory gating 
or behavioural inhibition. This differs from the literature which suggests females perform 
worse on measures of behavioural inhibition (Melynyte et al., 2017; Sowell et al., 2007). 
Ultimately this study provides some evidence that cannabis users who begin moderate 
use later in life differ from those with earlier more consistent heavy use on neural 
markers of inhibition and sensory gating. This thesis also further highlights the need for 
the inclusion of males and females in all sensory gating and behavioural inhibition 
research, as inconsistencies within the findings are not able to be properly interpreted due 
to lack of prior research including female participants. Overall, this study suggests that 
those who begin moderate cannabis use later in life have largely intact early sensory 
gating pathways while the later processing (N100 and P200) pathways may be impacted.  
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Table 1.  
Participant Demographic Information by Cannabis Use Group 
  Cannabis users  
(CUs; n = 14) 
M (± SD) 
Non-users 
(NUs; n = 16) 
M (± SD) 
Signifiance  
Sex M(F)  
 Male 9 4  
 Female 5 12  
Age (yrs)  21.64 (2.21) 23.87 (4.03) p = .07 
Education (yrs)  14.29 (1.98) 14.87 (2.75) p = .50 
Weekly Alcohol 
Consumption 
 2.48 (3.67) 1.30 (2.21) p = .30 
AUDITa  6.92 (4.78) 2.31 (2.02) p = .004 
WHO ASSISTb     
 Tobacco 6.00 (6.61) .31 (.87) p = .002 
 Alcohol 12.14 (8.26) 6.31 (4.06) p = .02 
 Cannabis 17.71 (8.98) 0.75 (1.34) p < .001 
 Cocaine 3.64 (6.03) 0.19 (0.75) p = .03 
 Amphetamines 1.21 (2.32) 0.00 (---) - 
 Inhalants 0.00 (---) 0.00 (---) - 
 Sedatives 2.64 (6.66) 0.00 (---) - 
 Hallucinogens 3.14 (4.19) 0.00 (---) - 
 Opioids 1.86 (5.33) 0.00 (---) - 
 Other drugs .64 (2.40) 0.00 (---) - 
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ReSUSc     





1.03 (.94) -  
 Individual 
enhancement 




.64 (.79) -  
Years of Cannabis 
use 
 3.77 (3.03) -  
Weekly Cannabis 
Consumption  
 4.70 (2.71) -  
Note. Means and standard deviations provided for cannabis users and non-users.  
AUDIT - alcohol use disorders identification test; WHO ASSIST – World Health 
Organization, Alcohol Smoking and Substance Involvement Screening Test; ReSUS – 
Reasons for Substance Use Scale. 
Weekly alcohol consumption measured as number of standard drinks per day. Weekly 
cannabis consumption measured as number of time cannabis is consumed per week. 
Years of cannabis use was generated based on when the user began regular consistent 
use.  
a = Scores rang 0-20+ and indicate risky drinking behaviour, scores 0-7 = low risk, 8-15 = 
risky or hazardous, 16-19 = High risk, 20 + High risk, almost certainly dependent.  
b = scores 0-3 suggest no intervention is needed while scores 4-26 suggest brief 
intervention and score 27+ suggest more intensive treatment is needed. 
c = Average scores generated for each subscale with higher totals indicating more 
motivation to use for these reasons. 
d = scores range from 5 – 15 with lower scores indicate more paranoid and suspicious 
feelings.  
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Table 2.  
Frequency Rating for Cannabis Users on The Reasons for Substance Use Scale (ReSUS) 
Reason for use   n (%) 
Coping with Distressing Emotions and Symptoms Subscale  
When I am experiencing unpleasant thoughts    
 Never 3 (21.4) 
 Sometimes 5 (35.7) 
 Often  2 (14.3) 
 Almost Always 4 (23.6) 
When I feel ashamed or bad about myself   
 Never 4 (28.6) 
 Sometimes 7 (50) 
 Often  1 (7.1) 
 Almost Always 2 (14.3) 
When I am thinking about bad things that 
have happened in the past 
  
 Never 6 (42.9) 
 Sometimes 6 (42.9) 
 Often  1 (7.1) 
 Almost Always 1 (7.1) 
When my thoughts are racing    
 Never 6 (42.9) 
 Sometimes 3 (21.4) 
 Often  3 (21.4) 
 Almost Always 2 (14.3) 
When I want to escape from my problems and 
worries 
  
 Never 3 (21.4) 
 Sometimes 3 (21.4) 
 Often  5 (35.7) 
 Almost Always 3 (21.4) 
When I feel suspicious or paranoid   
 Never 11 (78.6) 
 Sometimes 2 (14.4) 
 Often  1 (7.1) 
 Almost Always 0 
When I am feeling depressed   
 Never 3 (21.4) 
 Sometimes 3 (21.4) 
 Often  5 (35.7) 
 Almost Always 3 (21.4) 
When I am angry at the way things have 
turned out 
  
 Never 5 (35.7) 
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 Sometimes 4 (28.6) 
 Often  2 (14.3) 
 Almost Always 3 (21.4) 
When I feel anxious or tense   
 Never 4 (28.6) 
 Sometimes 5 (35.7) 
 Often  2 (14.3) 
 Almost Always 3 (21.4) 
When I start to feel guilty about something   
 Never 7 (50) 
 Sometimes 5 (35.7) 
 Often  2 (14.3) 
 Almost Always - 
When I am feeling stressed   
 Never 1 (7.1) 
 Sometimes 2 (14.3) 
 Often  7 (50) 
 Almost Always 4 (28.6) 
When I am having trouble sleeping   
 Never 3 (21.4) 
 Sometimes 4 (28.6) 
 Often  3 (21.4) 
 Almost Always 4 (28.6) 
When I feel I have been discriminated against    
 Never 9 (64.3) 
 Sometimes 4 (28.6) 
 Often  1 (7.1) 
 Almost Always - 
When I am hearing sounds or voices that 
other people can’t hear 
  
 Never 13 (92) 
 Sometimes 1 (7.1) 
 Often  - 
 Almost Always - 
When I am having trouble thinking or 
concentrating  
  
 Never 7 (50) 
 Sometimes 5 (35.7) 
 Often  2 (14.3) 
 Almost Always  
When I am having trouble communicating 
with others  
  
 Never 11 (78.6) 
 Sometimes 1 (7.1) 
 Often  1 (7.1) 
 Almost Always 1 (7.1) 
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When I am in pain physically   
 Never 6 (42.9) 
 Sometimes 3 (21.4) 
 Often  1 (7.1) 
 Almost Always 4 (28.6) 
When I am feeling lonely   
 Never 4 (28.6) 
 Sometimes 4 (28.6) 
 Often  4 (28.6) 
 Almost Always 1 (7.1) 
Social Enhancement & Intoxication subscale    
When I am feeling happy and content with 
my life  
  
 Never 1 (7.1) 
 Sometimes 3 (21.4) 
 Often  7 (50) 
 Almost Always 2 (14.3) 
When I want to feel good, have a laugh or be 
happier 
  
 Never 1 (7.1) 
 Sometimes 1 (7.1) 
 Often  4 (28.6) 
 Almost Always 7 (50) 
When I am with friends and we want to have 
a good time  
  
 Never 2 (14.3) 
 Sometimes - 
 Often  3 (21.4) 
 Almost Always 7 (50) 
When I want to chill out or relax   
 Never - 
 Sometimes 1 (7.1) 
 Often  4 (28.6) 
 Almost Always 8 (57.1) 
When I think about how good it tastes   
 Never 7 (50) 
 Sometimes 1 (7.1) 
 Often  1 (7.1) 
 Almost Always 4 (28.6) 
When I feel excited about something   
 Never 3 (21.4) 
 Sometimes 5 (35.7) 
 Often  3 (21.4) 
 Almost Always 3 (21.4) 
When I want to fit in with other people    
 Never 7 (50) 
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 Sometimes 4 (28.6) 
 Often  3 (21.4) 
 Almost Always -  
When I want to feel drunk, stoned, or high   
 Never -  
 Sometimes 1 (7.1) 
 Often  7 (50) 
 Almost Always 6 (42.9) 
When I feel under pressure from other to use 
drugs/drink alcohol 
  
 Never 9 (64.3) 
 Sometimes 3 (21.4) 
 Often  1 (7.1) 
 Almost Always 1 (7.1) 
When I have been drinking and think about 
using drugs (or vice versa) 
  
 Never 4 (28.6) 
 Sometimes 5 (35.7) 
 Often  4 (28.6) 
 Almost Always 1 (7.1) 
When I’m bored and want something to do to 
pass the time 
  
 Never - 
 Sometimes 6 (42.9) 
 Often  5 (35.7) 
 Almost Always 3 (21.4) 
Individual Enhancement Subscale  
When I want to feel more self-aware   
 Never 8 (57.1) 
 Sometimes 2 (14.3) 
 Often  3 (21.4) 
 Almost Always 1 (7.1) 
When I need motivation to do things   
 Never 7 (50) 
 Sometimes 5 (35.7) 
 Often  1 (7.1) 
 Almost Always 1 (7.1) 
When I want to stay awake or be more alert   
 Never 12 (85.7) 
 Sometimes 2 (14.3) 
 Often  - 
 Almost Always - 
When I want to feel more creative   
 Never 3 (21.4) 
 Sometimes 6 (42.9) 
 Often  4 (28.6) 
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 Almost Always 1 (7.1) 
When I want to feel more emotions    
 Never 4 (28.6) 
 Sometimes 6 (42.9) 
 Often  3 (21.4) 
 Almost Always 1 (7.1) 
When I want to feel sexy   
 Never 10 (71.4) 
 Sometimes 3 (21.4) 
 Often  1 (7.1) 
 Almost Always - 
When I am experiencing medication side 
effects 
  
 Never 12 (85.7) 
 Sometimes 1 (7.1) 
 Often 1 (7.1) 
 Almost Always - 
When I want to feel normal    
 Never 9 (64.3) 
 Sometimes 3 (21.4) 
 Often - 
 Almost Always 2 (14.3) 
When I want to feel more confident   
 Never 6 (42.9) 
 Sometimes 7 (50) 
 Often 1 (7.1) 
 Almost Always - 
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 Table 3.  
Mean Amplitude and Latency for the paired click paradigm  
  Paired Click Paradigm 
  CU (± SD) NU (± SD) 
P50 (Cz)    
 S1 1.75 μVa (1.14) 1.54μVa (1.20) 
 S2 0.55 μVa (.59) 0.64 μVa (.76) 
 RP50 0.32 μV (.36) 0.72 μV (1.37) 
 DP50  1.20 μV (1.38) 0.90 μV (1.07) 
 Latency S1 108.86 ms (7.47) 105.88 ms (5.44) 
 Latency S2 108.00 ms (8.01) 104.63 ms (4.11) 
N100 (Cz)    
 S1 -1.86 μV (2.28) -2.80 μV (3.31) 
 S2 -2.60 μV (2.40) -1.78 μV (1.84) 
 RN100 1.20 μV (1.83) .36 μV (.82) 
 DN100 .74 μV (2.98) -1.01 μV (2.63) 
 Latency S1 112.43 msa (28.07) 129.75 msa (33.47) 
 Latency S2 177.57 msa (27.65) 181.88 msa (19.66) 
P200 (Cz)    
 S1 0.01 μVb (3.32) 2.93 μVb (3.45) 
 S2 1.25 μV (2.87) 1.19 μV (2.23) 
 RP200 .71 μV (2.25) -.70 μV (2.56) 
 DP200 -1.24 μV (3.62) 2.71 μV (5.34) 
 Latency S1  142.14 msb (50.44) 190.38 msb (57.38) 
 Latency S2 227.71 ms (45.36) 234.75 ms (32.36) 
Note.  μV = Microvolts ;  ms = milliseconds  
a=  Stimulus Main Effect  p < .05  
b= Group Main Effect p < .05 
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Table 4.  
Main and interaction effects of the paired click paradigm CU vs NU 
  df F statistic Significance 
(p – value) 
Hedges’ g 
  Amplitude 
P50       
 Stimulus 1,28 22.23 p < .001 g = 1.09 
 Group 1,28 .05 p = .82 g = .05 
 Stimulus*Group 1,28 .45 Overall: p = .51 
S1: p = .62 
S2: p = .73 
S1: g =.18 
S2: g =.12 
 
N100      
 Stimulus 1,28 .074 p = .79 g = .079 
 Group 1,28 .007 p = .94 g = .02 
 Stimulus*Group 1,28 2.92 Overall: p = 
.098 
S1: p = .38 
S2: p = .30 
S1: g =.30 
S2: g =.38 
 
P200      
 Stimulus 1,28 .118 p = .73 g = .011 
 Group 1,28 3.04 p = .09 g = .48 
 Stimulus*Group 1,28 4.14 Overall: p = .05 
S1: p = .02 
S2: p = .95 
S1: g = .86 
S2: g = .02 
 
  Latency 
P50      
 Latency  1,28 1.88 p = .18 g = .16 
 Group  1,28 1.93 p = .18 g = .47 
 Latency*Group 1,28 .065 Overall: p = .80 
S1: p = .22 
S2: p = .18 
S1: g = .46 
S2: g = .50 
 
N100      
 Latency 1,28 91.09 p < .001 g = 2.09 
 Group 1,28  1.81 p = .19 g = .40 
 Latency*Group 1,28 1.12 Overall: p = .30 
S1: p = .14 
S2: p = .62 
S1: g =.55 
S2: g =.18 
 
P200      
 Latency 1,28 39.56 p < .001 g = .01 
 Group 1,28 3.96 p = .06 g = .60 
 Latency*Group 1,28 3.98 Overall: p = .06 
S1: p = .02 
S2: p = .63 
 
S1: g =.61 
S2: g =.17 
 
Note. F-statistic and p-values are based on the Greenhouse-Geiser correction to account 
for sphericity violations in our data. 
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Table 5. 
Main effects of ratio and difference scores across the Paired Click Paradigm 
 
  df F statistic Significance 
(p – value) 
Hedges’ g 
P50       
 rP50 1,28 1.14 p = .30 g = .40 
 dP50 1,28 .45 p = .51 g = .24 
 
N100      
 rN100 1,28 2.70 p = .11 g = .80 
 dN100 1,28 2.92 p = .098 g = .63 
Note. F-statistic and p-values are based on the Greenhouse-Geiser correction to account 
for sphericity violations in our data. 
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Table 6.  
Main and interaction effects of the paired click paradigm Male vs Female covarying for 
weekly cannabis use 
  df F statistic Significance 
(p – value) 
Hedges’ g 
  Amplitude 
P50       
 Stimulus 1,27 7.00 p = .01 g = 1.11 
 Sex  1,27 .66 p = .42 g = .22 
 Stimulus*Sex 1,27 2.67 Overall p = .13 
S1:  p = .08 
S2: p = .46 
S1: g =.41 
S2: g =.10 
 
N100      
 Stimulus 1,27 1.12 p = .29 g = .079 
 Sex 1,27 .22 p = .64 g = .14 
 Stimulus*Sex 1,27 .399 Overall: p = .29 
S1: p = .92 
S2: p = .22 
S1: g =.10 
S2: g =.20 
 
P200      
 Stimulus 1,27 1.48 p = .23 g = .11 
 Sex 1,27 .05 p = .83 g = .023 
 Stimulus*Sex 1,27 1.39 Overall: p = .25 
S1: p = .49 
S2: p = .24 
 
S1: g = .17 
S2: g = .19 
 
  Latency 
P50      
 Stimulus  1,27 3.25 p = .082 g = .16 
 Sex 1,27 .20 p = .66 g = .09 
 Stimulus*Sex 1,27 .006 Overall: p = .94 
S1: p = .99 
S2: p = .97 
S1: g = .04 
S2: g = .14 
 
N100      
 Stimulus 1,27 38.06 p < .001 g = 2.08 
 Sex 1,27 1.39 p = .25 g = .28 
 Stimulus*Sex 1,27 1.32 Overall: p = .26 
S1: p = .36 
S2: p = .73 
S1: g =.38 
S2: g =.14 
 
P200      
 Stimulus 1,27 11.11 p = .002 g = 1.28 
 Sex 1,27  2.67 p = .11 g = .33 
 Stimulus*Sex 1,28 1.71 Overall: p = .20 
S1: p = .30 
S2: p = .81 
S1: g =.41 
S2: g =.23 
 
Note. F-statistic and p-values are based on the Greenhouse-Geiser correction to account 
for sphericity violations in our data. 
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Weekly cannabis use has been added to the model as a covariate. 
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Table 7. 
Main effects of ratio and difference scores across the Paired Click Paradigm Males vs 
Females 
 
  df F statistic Significance 
(p – value) 
Hedges’ g 
P50       
 rP50 1,27 .54 p = .59 g = .18 
 dP50 1,27 1.46 p = .25 g = .45 
 
N100      
 rN100 1,28 1.43 p = .26 g = .47 
 dN100 1,28 .68 p = .51 g = .009 
P200      
 rP200 1,28 2.07 p = .14 g = .63 
 dP200 1,28 2.78 p = .08 g = .47 
Note. F-statistic and p-values are based on the Greenhouse-Geiser correction to account 
for sphericity violations in our data. 
Weekly cannabis use has been added to the model as a covariate.  
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Table 8.  
Means and Standard deviations in addition to main effects of the behavioural measures of 
the  Go/NoGo paradigm 
 CU 
M (± SD) 
NU 
M (± SD) 
F Significance 
(p – value)  
Percent Correct  97.16 (2.77) 97.81 (1.47) .64 p = .43 
RT Correct response 360.54 ms (53.68) 361.81 (51.07) .004 p = .95 
False Alarm 35.08 (17.90) 35.31 (14.41)    .002 p = .97 
RT False Alarm 361.10 ms (63.38) 363.05 (50.94) .009 p = .93 
Miss  12.77 (12.50) 9.88 (6.63) .64 p = .43 
 Male 
M (± SD) 
Female 
M (± SD) 
F Significance 
(p – value)  
Percent Correct  97.17 (2.38) 97.77 (1.98) .54 p = .47 
RT Correct response 376.31 (49.92) 350.60 (51.02) 1.82  p = .19 
False Alarm 34.67 (15.67) 35.59 (16.31) .023 p = .88 
RT False Alarm 374.82 (57.84) 353.26 (54.25) 1.05 p = .31 
Miss  12.75 (10.75) 10.06 (8.92) .54 p = .46 
Note.  ms = Milliseconds, RT = Reaction time  
RT for correct responses and false alarms are proportional to the number of correct 
responses and false alarms per block of the task.  
Percent correct represents the correct responses made across all four blocks of the task. 
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Table 9.  
Main and interaction effects of cannabis users versus non-users on the Go/NoGo 
paradigm  
   df F statistic Significance 
(p – value) 
Hedges’ g 
   Amplitude 
P100 (Go)        
 Region  1,27 14.05 p = .001 g = .52 
 Region*Group  1,27 1.10 p = .30 g = .50 
P300 (Go)       
 Region  1,27 33.08 p < .001 g = .03 
 Region*Group  1,27 .28 p = .60 g = .50 
P100 
(NoGo) 
      
 Region   1,27  21.14 p < .001 g = .60 
 Region*Group  1,27 1.19 p =.28 g = .52 
P300 
(NoGo) 
      
 Region  1,27 38.98 p < .001 g = .74 
 Region*Group  1,27 .43 p = .52 g = .01 
   Latency 
P100 (Go) Group 1,28 .20 p = .66 g = .16 
P300 (Go) Group 1,28 .44 p = .52 g = .25 
P100 
(NoGo) 
Group 1,28 .007 p = .93 g = .03  
P300 
(NoGo) 
Group 1,28 .60 p = .43 g = .28 
       
Note. F-statistic and p-values are based on the Greenhouse-Geiser correction to account 
for sphericity violations in our data. Latency was only examined between groups at the 
site of maximal amplitude. 
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Figure 1.  










Figure 2.  
N100/P200 amplitudes to the Paired Click paradigm (Stimulus 1 (a), and Stimulus 2 (b)) 
between cannabis users and non-users  
a) 
 






Figure 3.  
Difference (dN100) and ratio (rN100) measures of N100-indexed sensory gating in 






Figure 4.  






Figure 5.  
Main effect of P200 latency showing trend level interactions between stimulus type and 
group for the paired click paradigm. 
 
  
p = .056 
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Figure 6.  








N100/P200 amplitudes to the Paired Click paradigm (Stimulus 1 (a), and Stimulus 2 (b)) 

























Note. Go/NoGo paradigm depicting the ‘go’ stimuli (click) and ‘NoGo’ stimuli (no 
click/click inhibition). The stimuli in this paradigm are white numbers presented on a 
black computer screen. A response in the form of a click indicates a ‘Go’ trial while no-
click indicates a ‘NoGo’ or inhibition trial. Participants only inhibit the response if the 
number presented is a duplicate of that preceeding it (e.g., 6,6). 
  
1 7 6 6 1 
Time (ms) 
Stimuli:  
Response: Click Click Click Click 
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Figure 9.  







Figure 10.  










Figure 11.  










Cannabis users and non-users needed for a research 
study on brain function 
 
 
If you are a regular cannabis user or a cannabis non-user, you may be 
eligible to participate in a research study investigating how cannabis affects 
brain function in males and females. 
 
Each participant will attend two 2-hour visits where they will complete 
questionnaires and computer-based tasks. Electroencephalography (EEG) 
will be recorded in order to measure brain function during performance of 
the computer tasks.  
 





If you are interested and want more information, please contact the lab of 







                  
 
Informed Consent Form Non-Interventional Study 
 
STUDY TITLE:  
 
Differential Effects of Cannabis Use on 
Event-Related Potential (ERP)-Indexed 
Brain Function in Males and Females 
 
PRINCIPAL INVESTIGATOR: Dr. Derek Fisher, Psychiatry 
EVR427-166 Bedford Highway  
Halifax, Nova Scotia, B3M2J6 
(902)457-5503 
 
SUB-INVESTIGATORS:  Candice Crocker, Ph.D. 
Departments of Psychiatry & Radiology 
 
Sherry Stewart, Ph.D., C.Psych. 
Department of Psychiatry 
 
Philip Tibbo, M.D., 
Department of Psychiatry 
 
FUNDER:   This study is being funded by a Catalyst 




You have been invited to take part in a research study. Taking part in this study is 
voluntary. It is up to you to decide whether to be in the study or not. Before you decide, 
you need to understand what the study is for, what risks you might take and what benefits 
you might receive. This consent form explains the study. You may take as much time as 
you wish to decide whether or not to participate. 
 
Please ask the research team to clarify anything you do not understand or would like to 
know more about.  Make sure all your questions are answered to your satisfaction before 
deciding whether to participate in this research study.   
 
The researchers will: 
Discuss the study with you 
Answer your questions 
Be available during the study to deal with problems and answer questions 





You are being asked to consider participating in this study because you have volunteered 
to participate as a) a regular cannabis user; or b) a cannabis non-user. 
 
If you decide not to take part or if you leave the study early, your usual health care will 
not be affected. 
2. Why Is This Study Being Conducted? 
 
Cannabis use within the previous 12 months in the Canadian population was reported at 
12.3% in 2015. The typical age of initiation of cannabis is between 13-15 years of age; 
cannabis use at this time point and through adolescence overlaps with changes in the 
structure and function of the brain that may be influenced by cannabis. This appears to 
produce changes in the way the brain works. What is unclear, however, is whether 
cannabis use produces different effects in males and females. Therefore, our research 
question is whether the changes that have been seen in brain activity in people who use 
cannabis can be seen in males only, in females only, or in both. By better understanding 
sex-based differences in brain activity following cannabis user, this work will tell us 
more about how cannabis effects the brain and possibly eventually influence public 
health guidelines. 
3. How Long Will I Be In The Study? 
 
You will be in this study for two 2-hour sessions (i.e. 4 hours total).  
 
4. How Many People Will Take Part In This Study? 
 
It is anticipated that about 60 regular cannabis users (30 male and 30 female) and 60 
cannabis non-users (30 male and 30 female) will participate in this study throughout 
Nova Scotia. All people will participate in this study at the QEII Health Sciences Centre 
or at Mount Saint Vincent University. 
5. How Is The Study Being Done?  
 
We can study how the brain reacts to incoming information, such as sounds, by 
measuring the brain’s electrical activity.  This can be done by placing electrodes on the 
surface of the scalp, a procedure called an electroencephalogram (EEG).  An EEG is a 
non-painful procedure that allows us to examine brain function during the processing of 
sounds in a quick and easy way.  
 
This study is being conducted using EEG recording equipment at the Neuroimaging 
Research Lab located at the QEII Health Sciences Centre and the EEG lab at Mount Saint 
Vincent University.  There will also be some questionnaires that each participant will be 
required to complete asking about your use of cannabis, alcohol and nicotine, as well as 
aspects of mental health.   
6. What Will Happen If I Take Part In This Study? 
 
 
If you agree to participate and sign the consent form and you are eligible to participate, 
you will be required to come to the Neuroimaging Research Lab for two, 2-hour session. 
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You will be asked to not use alcohol, cannabis products (such as marijuana), illegal drugs 
and over-the-counter drugs beginning at midnight prior to the test session. Participants 
should still take any prescribed drugs as they normally would. Upon arrival, a urine test 
will be conducted to ensure you did not use alcohol, cannabis or other drugs prior to the 
test session. If it is determined that you were unable to abstain from these substances, the 
test session will be cancelled and rebooked. The test session will usually take place 
between 10:00 a.m. – 12:00 p.m.  In the test session, sensors will be placed on your scalp 
and around your eyes to monitor electrical activity of the brain. In order to properly place 
the sensors, we will put an EEG cap on your head; the cap is made of a stretchy nylon-
like material and fits snugly to your head. Once the sensors are in place, your brain 
activity will be recorded while you are watching a silent, neutral video (for example, a 
nature film like “Planet Earth”). At the same time as you are watching the film, sounds 
will be presented through headphones. The process of setting up the sensors and 
recording brain activity will take approximately 1.5 hours. Small breaks in the recording 
process will be integrated into the test session. Five (5) questionnaires asking you about 
your cannabis use (such as how often you use, when you started using, etc…), general 
drug consuming behaviour, and about specific thoughts and experiences (such as hearing 
voices or feeling like your thoughts are being controlled) will also be completed so we 
can better understand how these might affect your brain activity. You will also be asked 
to provide a saliva sample to assess circulating hormone levels (such as estradiol and 
testosterone). You have a right to skip any questions you do not wish to answer. A 
member of the study team will always be with you. 
 
If at any point you change your mind and you no longer wish to participate in the study 
you can withdraw from the study.  Your decision to withdraw will not affect your health 
care in any way. 
 
7. Are There Risks To The Study? 
 
There are risks with this, or any study. To give you the most complete information 
available, we have listed some possible risks. We want to make sure that if you decide to 
try the study, you have had a chance to think about the risks carefully. Please be aware that 
there may be risks that we don’t yet know about. 
 
EEG 
You will be required to wear an electrode cap; though unlikely, wearing the cap may 
produce a headache. The electrode sensors may result in temporary redness and irritation 
of the skin that will disappear in a few hours. Additionally, you will be asked to sit for 2 
hours during the test session. 
 
QUESTIONNAIRES 
You may find the interviews and questionnaires you receive during the course of the 
study upsetting or distressing. You may not like all of the questions that you will be 




To protect your information, we will not keep your name or other information that may 
identify you with your study data, only a code number. Files that link your name to the 
code number will be kept in a secure place. Although no one can absolutely guarantee 
confidentiality, using a code number makes the chance much smaller that someone other 
than the research staff or other authorized groups or persons (discussed later in the 
consent form) will ever be able to link your name to your study data. 
8.  Are There Benefits Of Participating In This Study? 
We cannot guarantee or promise that you will receive any benefits from this research. 
However, possible benefits include a sense of contributing to a greater understanding of 
how cannabis affects the brain. There are no direct medical benefits to participating in 
this study. 
 
9. What Happens at the End of the Study? 
 
Once you have completed the study procedures your participation in the study is over. 
 
It is anticipated that the results of this study will be published and or presented in a 
variety of forums. In any publication and/or presentation, information will be provided in 
such a way that you cannot be identified.  
 
You may leave your mailing/email address with a member of the study team if you wish 
to receive a copy of the results and/or any publications that result from the study.   The 
results will be forwarded to you once the study has been completed and all the data has 
been analyzed. 
 
10. What Are My Responsibilities? 
 
As a study participant you will be expected to: 
Follow the directions of the research team; 
Report all medications being taken or that you plan on taking; 
Report any changes in your health to the research team; 
Report any problems that you experience that you think might be related to participating 
in the study; 
Not consume alcohol, cannabis (such as marijuana), caffeine (including coffee, tea and 
cola), illegal drugs and over-the-counter drugs beginning at midnight before each test 
session 
 
11. Can My Participation in this Study End Early? 
 
Yes.  If you chose to participate and later change your mind, you can say no and stop the 
research at any time. If you wish to withdraw your consent please inform the research 
team.  If you choose to withdraw from this study, your decision will have no effect on 
your current or future medical treatment and healthcare. If you decide to withdraw from 
the study, the information collected up to that time will continue to be used by the 
research team. It may not be removed. 
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Also, the Nova Scotia Health Authority Research Fund, the Nova Scotia Health Authority 
Research Ethics Board and the principal investigator have the right to stop patient 
recruitment or cancel the study at any time. 
 
Lastly, the principal investigator may decide to remove you from this study without your 
consent for any of the following reasons:  
 
You do not follow the directions of the research team; 
There is new information that shows that being in this study is not in your best interests; 
 
If you are withdrawn from this study, Dr. Derek Fisher will discuss the reasons with you 
and plans will be made for your continued care outside of the study, if needed. 
 
12. What About New Information? 
 
You will be told about any other new information that might affect your health, welfare, 
or willingness to stay in the study and will be asked whether you wish to continue taking 
part in the study or not. 
 
13. Will It Cost Me Anything? 
 
There is no fee for participating in the study, although you may need to pay for 
medications to treat the side effects that you may experience as a result of participating in 
this study. Your private health care insurer may not pay for any or all of these added costs 
 
You will not be paid to be in the study. You will be compensated $25 for each session to 
cover meals and transportation costs on the study visit day.  
 
Research Related Injury 
 
If you become ill or injured as a direct result of participating in this study, necessary 
medical treatment will be available at no additional cost to you. Your signature on this 
form only indicates that you have understood to your satisfaction the information 
regarding your participation in the study and agree to participate as a subject. In no way 
does this waive your legal rights nor release the principal investigator, the research staff, 
the study sponsor or involved institutions from their legal and professional 
responsibilities. 
 
14. What About My Privacy and Confidentiality? 
 
Protecting your privacy is an important part of this study. Every effort to protect your 
privacy will be made. If the results of this study are presented to the public, nobody will 
be able to tell that you were in the study. 
 
However, complete privacy cannot be guaranteed. For example, the principal investigator 
may be required by law to allow access to research records.  
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If you decide to participate in this study, the research team will collect personal health 
information and collect only the information they need for this study. “Personal health 
information” is health information about you that could identify you because it includes 
information such as your; 
Name,  
Address,  
Telephone number,  
Age or month/year of birth (MM/YY),  
Information from the study interviews and questionnaires; 
 
Access to Records 
 
Other people may need to look at your personal health information to check that the 
information collected for the study is correct and to make sure the study followed the 
required laws and guidelines.  These people might include: 
 
The Nova Scotia Health Authority Research Ethics Board (NSHA REB) and people 
working for or with the NSHA REB because they oversee the ethical conduct of research 
studies within the Nova Scotia Health Authority. 
 
These people will view your study records at this institution and will not take identifying 
information away with them. 
 
Use of Your Study Information  
 
The research team and the other people listed above will keep the information they see or 
receive about you confidential, to the extent permitted by applicable laws. Even though 
the risk of identifying you from the study data is very small, it can never be completely 
eliminated. 
 
The research team will keep any personal health information about you in a secure and 
confidential location for 7 years after the publication of data and then destroy it according 
to NSHA policy. This information will initially be held in the PI’s private, locked office 
at Mount Saint Vincent University and will be transferred to locked storage at the QEII 
Centre for Clinical Research once the study data is published. Your personal health 
information will not be shared with others without your permission.  
 
After your part in the study ends, we may continue to review your health records for 
safety and data accuracy until the study is finished or you withdraw your consent. 
Additionally, we may want to follow your progress and to check that the information we 
collected is correct. 
 
You have the right to be informed of the results of this study once the entire study is 
complete.   
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The REB and people working for or with the REB may also contact you personally for 
quality assurance purposes. 
 
Your access to records 
 
You have the right to access, review, and request changes to your study data. You may 
access these records at any time until the records are destroyed, however changes to study 
data may not be possible once the study data has been analyzed and published.  
 
15. Declaration of Financial Interest 
 
The Canadian Institutes of Health Research is reimbursing the principal investigator 
and/or the principal investigator’s institution to conduct this study. The amount of 
payment is sufficient to cover the costs of conducting the study. The PI has no vested 
financial interest in conducting this study. 
 
16. What About Questions or Problems? 
 
For further information about the study you may call the principal investigator, who is the 
person in charge of this study and/or any other research team member listed below. 
 
The principal investigator is Dr. Derek Fisher. 
Telephone:  902.457.5503. 
Email: derek.fisher@msvu.ca 
 
If you experience any symptoms or possible side effects or other medical problems, 
please let the principal investigator or research coordinator know immediately. 
 
17. What Are My Rights? 
 
You have the right to all information that could help you make a decision about 
participating in this study. You also have the right to ask questions about this study and 
your rights as a research participant, and to have them answered to your satisfaction 
before you make any decision. You also have the right to ask questions and to receive 
answers throughout this study.  You have the right to withdraw your consent at any time.  
 
If you have any questions about your rights as a research participant, contact Patient 
Relations at (902) 473-2133 or healthcareexperience@nshealth.ca  
 
In the next part you will be asked if you agree (consent) to join this study. If the answer is 
“yes”, please sign the form. 
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Consent Form Signature Page 
 
I have reviewed all of the information in this consent form related to the study called: 
 
Differential Effects of Cannabis Use on Event-Related Potential (ERP)-Indexed 
Brain Function in Males and Females 
 
I have been given the opportunity to discuss this study. All of my questions have been 
answered to my satisfaction. 
 
This signature on this consent form means that I agree to take part in this study. I 
understand that I am free to withdraw at any time. 
 
 
______________________________        ___________________  _____  /  ____  /  ___ 




_______________________        _______________________         ______/____  /_____ 




_____________________________     _______________________ _____  /  ____ /  
____ 







I Will Be Given a Signed Copy Of This Consent Form 
 













ROMEO File #1024305  
SMU REB # 21-077 
Appendix B: Questionnaires 




Date: ___________________________  ID# :_________________________ 
 
Name: ___________________________ Age: _____   DOB (dd/mm/yyyy): 
_____________ 
 
Sex: _____  Education:  Grade school  0  1  2  3  4  5  6  7  8 
            High school 9  10  11  12 
            Trade/College     13  14 
            University 13  14  15  16 
            Master’s level     17  18 
            Ph.D. level 19  20  21 
 
Classification:  CF  /   CM   /   NF   /   NM 
 
Handedness:  Left / Right  Normal hearing: Y / N  Vision: Normal / 
Corrected 
 
Telephone: (h) ____________________  (w) __________________   
(c)___________________ 
 
What is your first language? _____________    Other languages you are fluent in? 
___________ 
Are you employed?  Y / N  If yes, what is your occupation? _____________ F/T or 
P/T?  




Are you currently on medication on a regular basis for any physical condition? Y / N 
Are you currently using any pain medication on a regular basis? Y / N 
Have you had any steroid use within the past 3 months? Y / N 
Do you have a condition that effects estrogen/progesterone or testosterone levels in your 
body? Y / N 
If they do exclude. – only if confirmed otherwise test and note. 
Have you ever been diagnosed with a psychiatric or mental illness (e.g. depression, 
anxiety)? Y / N  
If yes, what disorder was diagnosed? _________________________ 
Are you currently being seen for treatment? ___________________ 
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Do you currently receive medication for these illnesses? ______________ 
Have you ever been diagnosed with a learning disability? Y / N 
If yes, what disorder was diagnosed? _________________________ 
Have you had a head of brain injury in the past 6 months? Y / N 
If yes, did you lose consciousness for one or more hours? _________ 
 
To the best of your knowledge: 
Do you have any neurological disorders such as epilepsy, dementia, Parkinson’s disease? 
Y / N 
If yes, which? _____________________ 
 
What is your daily (or weekly) alcohol consumption? ________________________ 
Have you ever smoked cigarettes? Y / N 
If yes, do you currently smoke? ______________________ 
If no, when did you quit? _____________________ 
How many years have you been a smoker? _____________ 
How many cigarettes/day? __________________ 
How long at this rate? ______________________ 
Have you ever used cannabis? Y / N 
If yes, do you currently use it? _______________________ 
If no, when did you quit? _____________________ 
 How many times in your life have you used it? ___________ 
If yes, what is the THC/CBD content of your favourite strain?_____________ 
How many years have you smoked cannabis? __________________ 
How many times each week do you smoke? ____________________ 
 
Timeline follow-back (TFB) of cannabis use.  
TFB Week Start Date (mm/dd/yyyy) ________/________/______ 
 
Please indicate which of the following days cannabis was consumed over the past week, 
check each day that cannabis was consumed and report the date in the space provided. 
 
 
Sunday: __________  Wednesday: ________ Saturday: ____________ 
Monday: _________  Thursday: __________      
Tuesday: _________   Friday: ____________ 
 
Do you use any street drugs (cocaine, MDMA)? _______________ 
If yes, What drugs? _________________ 
 How often? _________________ 
 
FOR FEMALES: 
Do you have a regular menstrual cycle? Y / N 
Relatively regular cycle.  
Do you use oral contraceptives/ have you ever used oral contraceptives in the past 3 
months? Y/ N 
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What brand? _____________ 
Have you ever been pregnant? Y / N 
If yes, how many times (including births, miscarriages and abortions)? ______ 








Participant: ______________     Date: ____________ 














Reasons for Substance use Scale (ReSUS)  
Participant Code: _________ 
 
Please answer the following questions regarding when you typically feel like using 
cannabis: 
 















































































































































































































































































Alcohol Use Disorders Identification Test (AUDIT) 
 
1. How often do you have a drink containing alcohol? 
 
Never  Monthly Two to four Two to three Four or more 
                  or less times a month      times a week    times a 
week 
 
2. How many drinks containing alcohol do you have on a typical day when you are 
drinking? 
 
1 or 2  3 or 4  5 or 6  7 or 9  10 or more 
 
3. How often do you have six or more drinks on one occasion? 
 
Never Less than monthly Monthly Weekly Daily or almost daily 
 
4. How often during the last year have you found that you were not able to stop 
drinking once you had started? 
 
Never Less than monthly Monthly Weekly Daily or almost daily 
 
5. How often during the last year have you failed to do what was normally expected 
from you because of drinking? 
 
Never Less than monthly Monthly Weekly Daily or almost daily 
 
6. How often during the last year have you needed a first drink in the morning to get 
yourself going after a heavy drinking session? 
 
Never Less than monthly Monthly Weekly Daily or almost daily 
 
7. How often during the last year have you had a feeling of guilt or remorse after 
drinking? 
 
Never Less than monthly Monthly Weekly Daily or almost daily 
 
8. How often during the last year have you been unable to remember what happened 
the night before because you had been drinking? 
 
Never Less than monthly Monthly Weekly Daily or almost daily 
 
9. Have you or someone else been injured as a result of your drinking? 
 
No  Yes, but not in the last year  Yes, during the last year 
 
10. Has a relative or friend, or doctor or other health worker been concerned about 
your drinking or suggested you cut down? 
No  Yes, but not in the last year  Yes, during the last year 
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Appendix C: Study Timeline 
 Timeline 
 
Participant code:       Date:     
  
 




  Arrival and Consent (turn cell phone off) 
  Urine Sample Obtained 
  Questionnaires (ReSUS, AUDIT, ASSIST, FTND& cannabis preference) 
  Saliva sample 
  EEG set up 
 
 
  Optimal MMN      Filename:    
  
  (3 blocks) 
 
  Paired 50 Click      Filename:    
  
 
  Eyes-Closed Resting (3 minutes)   Filename:    
  
 
  NoGo P300      Filename:    
  
  (4 blocks) 
 
  Eyes-Open Resting (3 minutes)  Filename:      
  
  Novelty P3      Filename:    
  
  (4 blocks) 
  
 
  Clean up electrodes/cap 




Appendix D: COVID Limitations  
 Unfortunately, during the first year of this study, the global COVID-19 pandemic 
halted all data collection for my thesis. Data collection for this study began in early 
December 2019 after troubleshooting equipment and paradigms and obtaining ethical 
clearance for the study. On March 15th, 2020, data collection was shut down due to 
country-wide lockdowns to stop the spread of the virus. Unfortunately, the lockdowns 
lasted longer than originally anticipated and face-to-face research was unable to reopen at 
Mount Saint Vincent University (the site of the laboratory) until March 14th, 2021. When 
the lab was given the clearance to reopen, we had participants booked in on the first day 
possible day to ensure an adequate sample size for this study. Unfortunately, recruitment 
was not as easy as it had been pre-pandemic as students (a significant pool of 
participants) were now dispersed across the province, country, and world doing online 
learning. In addition, those who were interested in participating in our study often chose 
to wait until case numbers were 0 for a period of 2 weeks or longer before agreeing to 
come within 6-feet of another individual for our study. Due to the nature of EEG, it was 
not possible to complete testing from 6-feet away, and while approved protective 
measures were put in place by our laboratory, some participants were not comfortable 
with this and therefore chose to wait to participate. With recruitment looking better 
towards the end of March, at the beginning of April, it appeared as though the study 
would reach enough participants for a sex by cannabis group analysis. Unfortunately, this 
is when the province was hit with another wave of COVID-19 and was forced to go into a 
full provincial lock-down once again closing face-to-face research and forcing us to close 
the lab and rebook all scheduled participants. Therefore, with all of these lockdowns and 
interruptions in data collection, I had a total of 5.5 months to collect my full sample of 
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participants, 1.5 of which I was only able to run one participant per day due to the 
modified COVID-19 testing protocol. For the remaining 4 months, I was able to run a 
maximum of 2 participants per day to abide by our study guidelines. 
 
